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General introduction and 
outline of the thesis
2Introduction
Cryptococcosis is a systemic infectious disease caused by the encapsulated 
yeast Cryptococcus spp., acquired by inhalation of basidiospores present in the 
environment [1]. Meningoencephalitis is the main clinical manifestation, with 
serious evolution [2] and related to neurological sequelae as blindness, deafness, 
muscle weakness and dysphagia [3]. Besides central nervous system (CNS) infection, 
pulmonary and skin infection may be observed [4, 5]. Annually, approximately 
223.000 meningitis cases are reported in HIV patients around the world, with 
180.000 deaths in 2014 [6]. 
Cryptococcus yeasts are present in the environment and are frequently recovered 
from soil, dust, trees and wood [7, 8]. The species of C. neoformans and C. gattii 
complexes are the main etiologic agents of cryptococcosis [9]. Cryptococcus 
neoformans species complex is cosmopolitan and is involved with the majority 
of cryptococcosis cases among immunocompromised patients around the world, 
mainly the ones who received organ transplantation, use corticosteroids or have 
AIDS [10]. Cryptococcus gattii species complex is emergent, initially found in tropical 
and subtropical regions with recent expansion to cold and temperate climates, as 
British Columbia in Canada, Washington and Oregon in the United States, where 
cryptococcosis outbreaks by C. deuterogattii (VGIIa/AFLP6A) were reported [11-13]. 
The environmental dispersion is believed to occur due to fungus transport by wood 
products, water, air, animals, insects and humans [14].
Cryptococcus taxonomy
Cryptococcus is a basidiomycetous yeast that belongs to the tremellomycetes class 
and has species in the Tremellales, Trichosporonales and Filobasidiales orders 
[15, 16]. Cryptococcus genus has more than 100 species, but the species inside 
the C. neoformans and C. gattii complexes are medically important because they 
are the main etiologic agent of human and veterinary cryptococcosis [9, 15-21]. 
Cryptococcus taxonomy was revised recently, and many species were transferred to 
other genera, for example, C. laurentii was transferred to the genus Papilliotrema 
[15, 16, 22]. Cryptococcus neoformans varieties raised to species: C. neoformans 
(formerly C. neoformans var. grubii/genotypes AFLP1/VNI, AFLP1A/VNII and AFLP1B/
VNII) and C. deneoformans (formerly C. neoformans var. neoformans/genotype 
AFLP2/VNIV) [22]; and five genotypes of C. gattii species complex were raised 
to five species: C. gattii sensu stricto (AFLP4/VGI), C. bacillisporus (AFLP5/VGIII), C. 
deuterogattii (AFLP6/VGII), C. tetragattii  (AFLP7/VGIV) and C. decagattii (AFLP10/
VGIV) [22].
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Although the taxonomic revision was established after 15 years of debate, part of 
the scientific community prefers to use only the term “species complex” [23] to refer 
to the genotypes/species belonging to the complexes, despite the evidence which 
support the revision [24]. This divergence was debated during the taxonomy session 
at the “10th International Conference on Cryptococcus and Cryptococcosis” in 2017 in 
Foz do Iguaçú, Brazil. During the session, arguments for and against the taxonomic 
review were presented and, during the discussion, there was broad support for 
taxonomic review. In the present work, the taxonomy suggested by Hagen et al. 
(2015) was used to quote C. neoformans and C. gattii species complexes [22].
Cryptococcus spp. environmental niches
Environmental niches of C. neoformans and C. gattii has been widely investigated in 
the world, showing several environmental sources previously not considered for the 
presence of the fungus [25-28]. 
Cryptococcus neoformans s.s. (AFLP1/VNI) is the most prevalent species in the 
world and is responsible for the majority of cryptococcosis cases [29, 30]. However, 
C. deneoformans (AFLP2/VNIV) occurs more frequently in Europe and North America 
[30]. Cryptococcus neoformans species complex has been isolated mainly from pigeon 
droppings that are easily found in the urban perimeter [31-34], and from Passeriformes 
and Psitaciformes birds that live in domestic areas [35]. In addition, many tree species 
have been reported in the literature as environmental reservoirs of Cryptococcus, 
such as Colophospermum mopane, Acacia sp., Ziziphus mucronata, Eucalyptus sp., 
Olea europaea, Cassia sp., Ficus sp. and Tipuana tipu [34, 36-41].
The first environmental isolation of C. gattii s.l. were obtained from 
E. camaldulensis in Australia, indicating a specific association between C. gattii s.l. and 
E. camaldulensis in this region. According to Ellis and Pfeiffer (1990) the dispersion 
of C. gattii s.l. appeared to occur in late spring when the flowering period of 
E. camaldulensis started [42]. In addition, the distribution of E. camaldulensis 
corresponded to the region of endemic occurrence of cryptococcosis caused by 
C. gattii s.l. in Australia [42]. In other regions, C. gattii species complex has been 
isolated from a wide variety of trees, such as Acacia xanthophloea, Ceratonia siliqua, 
Corymbia ficifolia, Moquilea tomentosa and Pseudotsuga menziesii [27, 40, 43-45]. 
However, C. deuterogattii has also been recovered from wood houses’ dust [8] and 
C. gattii s.s. from avian droppings [35, 40].
Despite all studies in Cryptococcus spp. and cryptococcosis, the environmental 
reservoir and species diversity are unknown in many countries. The knowledge 
4of local epidemiology is important to recognize possible sources of human 
infection, as well as the most frequent species, and to trace the best measures of 
cryptococcosis prevention and control.
Virulence factors
Cryptococcus neoformans and C. gattii have the ability to cause infection in 
immunocompromised and immunocompetent people [9]. The size of infecting 
cells (1.8 – 3 µm) allows pulmonary alveoli invasion and arrest in brain capillary 
[1, 46, 47] and thermotolerance enables cell multiplication inside the host [48]. 
Protease and phospholipase enzymes are important for tissue invasion [49] and 
melanin production helps the fungus against the oxidative stress produced by host 
phagocytic cells [49]. As well as, superoxide dismutase is involved with resistance 
to oxygen radical-mediated damage addressed to cryptococcal cells inside 
macrophages [50]. 
Cryptococcus neoformans is able to proliferate inside macrophage’s phagosome 
[51, 52] and through this interaction cryptococcal cells may disseminate to other 
tissues, such as CNS, via Trojan horse mechanism [53, 54]. In addition to reach 
the CNS, paracytosis is used to cross tight junctions of brain endothelium [55] 
and transcytosis to move directly through the endothelial layer [56]. Urease 
facilitates cryptococcal transmigration by promoting damage to the microcapillary 
cells mediated by ammonia production, this increases the permeability of the 
entothelium and allows the dissemination to the brain [47, 57].
The polysaccharide capsule, composed of glucuronoxylomannan and 
galactoxylomannan, is an important virulence factor of cryptococcal cells involved 
in avoidance of phagocytosis. According to Bojarczuk and colleagues (2016), capsule 
size is a limiting factor of phagocytosis by macrophages that uptake more efficiently 
cryptococcal cells with small capsule size [58]. The cell size is another limiting factor, 
host mononuclear cells are unable to phagocytose titan cells because their giant 
size [59].
Immune response against Cryptococcus spp.
Cryptococcal mannose and beta glucan are the primary pathogen recognition 
motifs and are determinants in early interactions in the lung [60]. In addition, 
cryptococcal capsule accumulates C3 that facilitate phagocytosis [61, 62] by alveolar 
macrophages and dendritic cells in lungs [63]. Degraded cryptococcal components 
are loaded by major histocompatibility complex class II leading to adaptive 
immune system activation [64]. Th1 and Th17 profiles activate macrophages anti 
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cryptococcal activities associated with intracellular cryptococcal clearance [60, 
65]. However, cryptococcal capsule polysaccharides induce a Th2 profile leading to 
cryptococcal intracellular growth, high levels of anti-inflammatory cytokines and 
low levels of proinflammatory cytokines [52, 66]. Interestingly, Garro and colleagues 
(2010) showed that eosinophils phagocytose cryptococcal cells and drive to a Th1 
profile in rat cryptococcosis model and promote clearance of fungi [67].
Most studies drive to elucidate host immune responses during cryptococcosis are 
performed with human and animal cells stimulated with C. neoformans s.l., but 
recently the immune response against C. gattii s.l. has been investigated. Based on 
this, it is known that C. deuterogattii polysaccharide capsule blocks the recognition 
of surface antigens by dendritic cells and despite be internalized and killed by 
dendritic cells, the fungus evades maturation of this phagocytic cells resulting 
in no increase of TNF-α and suboptimal T-cell responses [68, 69]. According to 
Angkasekwinai and colleagues (2014), C. gattii s.l. infection compromises Th1 and 
Th17 differentiation and downregulates chemokine expression (IL-12 and IL-23), 
leading to inadequate protective immunity [70].
Antifungal susceptibility
Different in vitro antifungal susceptibility was found among Cryptococcus spp. 
Overall, C. gattii species complex have higher minimum inhibitory concentration 
(MIC) to azoles than C. neoformans species complex [39, 71, 72], this was also 
observed for amphotericin B and flucytosine [73]. In Brazil, C. deuterogattii (AFLP6/
VGII) clinical isolates showed high MIC values of flucytosine [74, 75] and fluconazole 
compared to C. neoformans s.s. (AFLP1/VNI) [74]. In addition, species inside 
the C. gattii species complex have different in vitro susceptibility. Cryptococcus 
deuterogattii (AFLP6/VGII) has high geometric mean MICs of flucytosine, fluconazole, 
voriconazole, itraconazole, posaconazole and isavuconazole when compared 
to C. gattii s.s. (AFLP4/VGI) [74, 76]. Lockhart and colleagues (2012) observed 
that C. deuterogattii (AFLP6/VGII) had high geometric mean MICs of fluconazole, 
followed by C. bacillisporus (AFLP5/VGIII), genotype VGIV (AFLP non-typed) and 
C. gattii s.s. (AFLP4/VGI) [77]. Despite the differences in antifungal susceptibilities 
among species, the initial therapy of cryptococcosis is chosen according to clinical 
manifestation and patient immune status [78].
Heteroresistance to antifungals is also observed among C. neoformans and 
C. gattii species complex when high concentration of itraconazole and fluconazole 
are tested [79, 80]. This phenomenon is related to phenotypic changes of 
cryptococcal cells as variation in cell and capsule size, decrease of ergosterol in the 
6cell wall, less susceptibility to oxidative stress and higher capability to proliferate 
inside macrophages [80]. These traits may be related to failure and relapses, but the 
clinical importance of the phenomenon is not elucidated [79-81].
Antifungal susceptibility tests are useful to investigate failure and relapses after 
therapy observed in patients treated with amphotericin B and azoles, but few 
data in the literature correlate clinical outcome with antifungal susceptibility [82]. 
Besides most Cryptococcus spp. isolates are susceptible to polyenes, flucytosine and 
azoles [75, 83], the prolonged use of fluconazole during meningitis maintenance 
therapies in HIV patients may select non-wild type isolates to this antifungal [84]. 
Cryptococcosis
The most frequent clinical manifestation of cryptococcosis is meningoencephalitis, 
which consists of subarachnoid space infection with involvement of cerebral 
parenchyma. The patients present nonspecific clinical features such as headache, 
fever, malaise, increased intracranial pressure and altered mental status [85]. Other 
signs are meningism, papillary edema, cranial nerve palsy, neurological deficit, 
depressed level of consciousness, cognitive impairment and gait ataxia due to 
obstructive hydrocephalus with ventricular dilatation [85].
Pulmonary cryptococcosis rarely develops as an acute process with clinical 
manifestations similar to other pulmonary diseases. Patients present weight loss, 
prolonged fever, anorexia, fatigue, cough, mucus or mucopurulent expectoration 
and hemoptysis [86]. Dyspnea and pleural pain may appear less frequently. Imaging 
exams show unilateral infiltrates, miliary micronodules, dense spherical lesions 
(cryptococcomas), and unilateral pleural effusions [2, 86].
Cutaneous lesions may be observed in patients with AIDS or with organ transplants, 
disseminated cryptococcosis, sarcoidosis, or who are receiving corticosteroids 
[2]. The initial lesion usually presents as a painless, ulcerative, acneiform or 
molluscum-like papule, with evolution to vegetative lesion. In patients with severe 
immunodeficiency, the lesions may be associated with vasculitis. The appearance 
of subcutaneous nodules is more common in patients who received high doses of 
corticosteroids [2].
In immunocompetent hosts, primary lung infection is often asymptomatic and 
controlled, remaining dormant. However, when the host’s immune system becomes 
compromised the infection can reactivate and than reach extra pulmonary sites 
such as the CNS [87].
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Outline of this thesis
The aims of this thesis were to investigate the molecular population structure of 
clinical and environmental Cryptococcus spp. isolates, to determine epidemiological 
and phylogenetic relationships, and test in vitro antifungal susceptibility. In 
addition, we investigated the in vitro cytokine induction by C. gattii species 
complex.
This thesis consists of two sections: Section I contains the chapters 2, 3 and 4 which 
focus on C. gattii species complex genetic diversity, global distribution and in vitro 
cytokine induction. Section II contains the chapter 5 on genetic diversity of C. 
neoformans sensu stricto.
Chapter 2 describes the ecoepidemiology of the C. gattii species complex in 
developing countries from different continents. Besides that, we discuss some 
aspects of C. gattii species complex antifungal susceptibility and bring insights on 
the revised Cryptococcus taxonomy.
Chapter 3 describes the molecular characterization of C. deuterogattii clinical 
isolates by amplified fragment length polymorphism (AFLP), mating-typing and 
multi-locus sequencing (MLST), and the characterization of in vitro antifungal 
susceptibility to amphotericin B, fluconazole, itraconazole, voriconazole, 
posaconazole, isavuconazole and flucytosine.
Chapter 4 describes a comparison of C. gattii species complex ability to induce 
in vitro cytokines and antimicrobial molecules in human peripheral blood 
mononuclear cells (PBMCs). For this study we used reference strains of the C. gattii 
species complex.
Chapter 5 describes the distribution of genotypes of clinical and environmental 
isolates of C. neoformans sensu stricto as well as the in vitro susceptibility of the 
most frequently used antifungal agents for the treatment of cryptococcosis. For 
this study, 219 Brazilian isolates of C. neoformans s.s. were characterized for mating-
type, serotype, AFLP, microsatellite pattern and antifungal susceptibility.
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Abstract
Cryptococcosis is a systemic infection caused by species of the encapsulated 
yeast Cryptococcus. The disease may occur in immunocompromised and 
immunocompetent hosts and is acquired by the inhalation of infectious propagules 
present in the environment. Cryptococcus is distributed in a plethora of ecological 
niches, such as soil, pigeon droppings, and tree hollows, and each year new reservoirs 
are discovered, which helps researchers to better understand the epidemiology of 
the disease. In this review, we describe the ecoepidemiology of the C. gattii species 
complex focusing on clinical cases and ecological reservoirs in developing countries 
from different continents. We also discuss some important aspects related to the 
antifungal susceptibility of different species within the C. gattii species complex and 
bring new insights on the revised Cryptococcus taxonomy.





Cryptococcosis is a systemic fungal disease caused by yeasts belonging to 
the Cryptococcus neoformans/C. gattii species complexes [1], affecting both 
immunocompetent and immunocompromised hosts and causing devastating 
diseases [2]. Cryptococcal meningitis is the most common mycosis associated with 
acquired immune deficiency syndrome (AIDS) patients with significant morbidity 
and mortality especially in sub-Saharan Africa, Asia, and Latin America [3]. It is 
estimated that approximately 225,000 new cryptococcal meningitis cases occur 
globally each year, the majority of which (73%) occur in sub-Saharan Africa [3].
Cryptococcus gattii sensu lato (s.l.) is an emerging pathogen, initially considered 
an endemic disease, affecting patients living in tropical and subtropical zones [4]. 
However, over time, the geographic distribution of C. gattii s.l. infections expanded 
to temperate climate regions including Canada and the USA [4–6]. In addition, 
many ecological niches have been investigated globally in an attempt to elucidate 
the environmental reservoirs [7–9].
In this review, we describe the ecological distribution of the C. gattii species 
complex and highlight the environmental reservoirs of this pathogen in developing 
countries. We also discuss some important points about the antifungal susceptibility 
of this species complex and changes in the Cryptococcus taxonomy that has recently 
been debated among researchers and clinicians.
Cryptococcus gattii species complex distribution in developing 
countries
The C. gattii species complex was initially found in tropical and subtropical areas 
[10], but during the past two decades, the expansion to temperate climate regions 
was increasingly reported [5, 6, 11–15]. The ecological niches of the C. gattii species 
complex has been thoroughly investigated, and many global studies revealed that 
a plethora of tree species may be colonized by these pathogenic fungi [1, 7–9, 13, 
14, 16–20]. The distribution of C. gattii species complex in developing countries is 
shown in the Figure 1 and Table 1. Based on these data, it became clear that the 
C. gattii species complex is not associated to a specific tree genus but that it has a 
predilection for plant/wood debris in general.
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Fig 1. Distribution of clinical and environmental Cryptococcus gattii species complex in developing 
countries.
Table 1. Cryptococcus gattii species complex in developing countries.
Continent Species Source Country












































C. deuterogattii Clinical Ivory Coast [60]


























C. tetragattii Clinical 
Veterinary
India [88]
s.s.: sensu stricto; s.l.: sensu lato.
Latin America
C. gattii sensu stricto (s.s.) (genotype AFLP4/VGI) is a major aetiologic agent of 
cryptococcosis among immunocompetent patients from Brazil [25–27], Colombia 
[29], Mexico [33, 34], Honduras [32], and Peru [35] and has caused pneumonia in a renal 
transplant patient from Argentina [21]. This pathogen has also been involved with a 
fatal infection in Cuba in an imported cheetah from South Africa [31]. In nature, this 
species was found in Psittaciformes excreta in Brazil [28] and some tree species, such as 
Tipuana tipu, Grevillea robusta, and Eucalyptus spp. in Argentina [22–24] and Ficus 
spp. in Colombia [30]. 
Table 1. Continued
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Cryptococcus deuterogattii (genotype AFLP6/VGII) has been isolated from clinical 
samples and has been involved in meningitis, cutaneous diseases, and lung 
infection in immunocompetent and HIV-positive patients from Brazil [25, 26, 36–
38], Colombia [29], Mexico [33, 34], and French Guiana [45]. From Brazil, it was also 
reported causing disease in dogs [39, 40]. Cryptococcus deuterogattii is found in a 
variety of ecological niches, being isolated from tree detritus in Puerto Rico [46], from 
Moquilea tomentosa, Plathymenia reticulata, and Senna sianea in Brazil [18, 41, 42] 
and from Eucalyptus spp. in Colombia [30]. In addition, C. deuterogattii was also 
isolated from indoor dust from typical wooden houses in Amazonas, Brazil, and from 
Guettarda acreana trees [43, 44].
The species C. bacillisporus (genotype AFLP5/VGIII) has been isolated from clinical 
samples from Colombian immunocompetent patients [29], as well as from patients 
in Mexico [33, 34], Cuba [88], Brazil [25], Guatemala, Paraguay, and Venezuela [48]. 
In the environment, Corymbia ficifolia and Ficus spp. trees have been reported as 
reservoirs in Colombia [30, 47] and Tipuana tipu in Argentina [23].
Cryptococcus tetragattii (genotype AFLP7/VGIV) has been found in Puerto Rico from 
tree detritus [46] and the molecular type VGIV has also been found in México and 
Colombia, but AFLP or MLST genotyping has not been performed to differentiate C. 
tetragattii (genotype AFLP7/VGIV) and C. decagattii (genotype AFLP10/VGIV) from 
each other [33–35]. Some of these isolates have been recently investigated and 
shown to belong to C. decagattii rather than to C. tetragattii [1].
Africa
On the African continent, most of the literature data consists in descriptions of the 
C. neoformans species complex’s ecological distribution and clinical involvement. 
But only few studies have found new C. gattii species complex members. In 
South Africa, HIV-positive and HIV-negative children and adults were reported 
to have cryptococcosis caused by C. gattii s.l., but no genotyping was performed 
to determine the species [51–53]. The same holds true for Botswana [49] and 
Rwanda, where cryptococcal meningitis cases with C. gattii s.l. were found [50]. 
Environmental niches of C. gattii s.l. were investigated in Zambia, where positive 
samples were found in Colophospermum mopane, Julbernadia globiflora, Eucalyptus 




Cryptococcus gattii s.s. (genotype AFLP4/VGI) has been recovered from HIV-positive 
patients, bird droppings, Acacia xanthophloea, and Eucalyptus saligna from Kenya 
[55], from HIV-positive patients with meningitis from Zimbabwe [57, 58], D.R. Congo 
[32], and South Africa [56]. The species C. deuterogattii (genotype AFLP6/VGII) was 
reported causing cryptococcosis in HIV-positive patients from Ivory Coast [59]. In 
addition, C. tetragattii (genotype AFLP7/VGIV) was found to be a major cause of 
meningitis in HIV-positive patients in Zimbabwe [57, 58] and was reported to cause 
cryptococcosis in patients from Botswana, Malawi, and South Africa [57, 60]. A South 
African veterinary C. tetragattii (genotype AFLP7/VGIV) isolate was closely related to 
environmental C. tetragattii isolates from Colombia, Puerto Rico, and Spain [57].
Asia
There have been many studies performed in developing Asian countries reporting 
C. gattii s.l. causing human diseases and the ecological niche of this species complex. 
Unfortunately, most of the isolates were not genotyped. Chen and colleagues (2000) 
performed a study in Taiwan with clinical cases of cryptococcosis during the 1980s 
and 1990s [70]. Infections by C. gattii s.l. occurred in 35.6% of patients during the 
study period. The cryptococcosis cases included both immunocompetent and 
immunocompromised patients with a predominance of central nervous system 
(CNS) diseases [70]. In China, C. gattii s.l. was isolated from a surgical wound [61]. 
In addition, in India, it was isolated from HIV-positive and HIV-negative patients 
[62, 63]. Environmental niches of C. gattii s.l. in India were recognized being tree 
hollows of Syzygium cumini, Ficus religiosa, Polyalthia longifolia, Azadirachta indica, 
Cassia fistula, Mimusops elengi, and Cassia marginata [64–68], and flowers, bark, and 
detritus of Eucalyptus camaldulensis and E. tereticornes [69].
Cryptococcus gattii s.s (genotype AFLP4/VGI) was isolated from patients with meningitis 
in Malaysia [80, 81] and India [76]; this species was also reported in clinical samples from 
Korean, Taiwanese, and Thai patients [79, 82, 83]. China has reported cryptococcosis 
cases in HIV-positive, HIV-negative, and immunocompetent patients [71–75]. The 
environmental source of Thai C. gattii s.s. is decaying wood inside a Castanopsis 
argyrophylla hollow [8], and in India this species was isolated from tree hollows [77, 78].
Cryptococcus deuterogattii (genotype AFLP6/VGII) has been isolated from chronic 
meningitis in Malaysia [80, 81], HIV-negative patients from Korea and India [79, 84, 
85], and immunocompetent patients in China [71, 74, 75]. In Thailand, this species 
was reported causing disease in HIV-positive and HIV-negative patients, as well as 
causing primary cutaneous cryptococcosis [83, 86]. However, the environmental 
niche of this species has not been reported.
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Cryptococcus bacillisporus (genotype AFLP5/VGIII) was found causing diseases 
in patients from Korea [79, 85], which is interesting because in Asia C. gattii s.s. 
and C. deuterogattii have a predominance among clinical samples. In India, the 
first environmental C. bacillisporus isolate was recovered from decaying wood of 
Manilkara hexandra [78]. 
Cryptococcus tetragattii (genotype AFLP7/VGIV) was isolated in India from several 
clinical sources, including an HIV-positive patient with meningitis, cutaneous 
lesions, and granulomas in HIV-negative patients. All these isolates were genetically 
similar to C. tetragattii found in Botswana, Africa. However, only one patient had 
previously travelled to Egypt [87].
A hypothesis to explain the differences in geographic distribution of 
C. gattii/C. neoformans species complexes was put forward by Casadevall and 
colleagues (2017). These authors hypothesized that it may be attributed to the 
breakup of the supercontinent Pangea. The physical separation of Cryptococcus 
species complexes was an important point for its speciation [89]. In addition, it was 
suggested that environmental events, such as wind, ocean currents, and animals, 
would be involved, driving the more recent speciation of Cryptococcus species 
complexes [89]. Despite all epidemiological studies carried out, there are many 
countries where the presence of cryptococcal molecular genotypes has not yet 
been explored [90].
Antifungal susceptibility among the C. gattii species complex
Among cryptococcal species, different antifungal susceptibility patterns have 
been observed. In general, the C. gattii species complex shows higher minimum 
inhibitory concentrations (MICs) of azoles than isolates from the C. neoformans 
species complex [68, 91, 92]. In addition, C. gattii s.l. clinical isolates from Taiwan 
showed higher amphotericin B and flucytosine MIC values than C. neoformans 
s.l. clinical isolates [70]. In Brazil, C. deuterogattii (genotype AFLP6/VGII) clinical 
isolates showed higher MIC values for flucytosine [93, 94] and fluconazole than C. 
neoformans s.s. (genotype AFLP1/VNI) [93].
However, different antifungal susceptibility profiles are also present within 
species of the C. gattii species complex. Cryptococcus deuterogattii (genotype 
AFLP6/VGII) has higher geometric mean MICs for flucytosine, fluconazole, 
voriconazole, itraconazole, posaconazole, and isavuconazole than C. gattii s.s. 
(genotype AFLP4/VGI) [95]. Lockhart and colleagues (2012) investigated the 
correlation of C. gattii species complex and its antifungal susceptibility [96]. 
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Cryptococcus deuterogattii (genotype AFLP6/VGII) had the highest geometric mean 
MIC for fluconazole, followed by C. bacillisporus (genotype AFLP5/VGIII), genotype 
VGIV (AFLP non-genotyped), while C. gattii s.s. (genotype AFLP4/VGI) had the lowest 
among species [96]. Trilles and colleagues (2012) also observed that C. deuterogattii 
isolates had higher MICs of azoles than C. gattii s.s. [93]. An Indian study showed 
that clinical and environmental C. gattii s.l. isolates had high fluconazole MICs [68]. 
However, despite these differences in antifungal susceptibility among cryptococcal 
species, the initial cryptococcosis therapy is the same; the clinical management 
changes are according to presentations and immune status but does not consider 
the species involved in the disease [97].
Another important point is the phenomenon of heteroresistance, the ability of 
adaptation to high concentrations of drugs, observed in C. gattii s.l. to itraconazole and 
fluconazole [98, 99]. The development of heteroresistance is related to phenotypic 
changes, such as a decrease in cell and capsule size, low ergosterol content in the 
cell wall, less susceptibility to oxidative stress, and a great ability to proliferate 
inside macrophages [98, 99]. This intrinsic mechanism present in members of the 
C. neoformans/C. gattii species complexes may contribute to a relapse of 
cryptococcosis during maintenance therapy [98, 100]. However, the clinical 
importance of heteroresistance is not yet clear and requires further investigation 
[100, 101].
The C. gattii species complex: four molecular types, five genotypes or 
five species
The taxonomy of the tremellomycetous yeasts has recently been revised [102, 103]. 
Since the genus Cryptococcus was described, it has grown out as a highly polyphyletic 
one that contained more than 100 species within the orders Filobasidiales, Tremellales, 
and Trichosporonales [102, 103]. The taxonomic revision of the genus Cryptococcus 
has been extensively discussed over the past two decades. At the 6th International 
Conference on Cryptococcus and Cryptococcosis (ICCC) debate, “How many species 
and varietal states are there?” [104], different hypotheses were discussed about the 
status of the C. neoformans/C. gattii species complex: Should the situation be kept in 
a “two-species division”? [105, 106]. Should it be divided into six species? [107, 108]. 
Eight? [109]. The hypotheses were supported based on different opinions about 
the definition of species. The first one was supported by the idea that phenetic, 
biological, and cladistic species concepts need to be used together to proper classify 
the agents of cryptococcosis, because genetic variation as shown by the molecular 
types does not always reflect their biological characteristics [105, 106, 110]. However, 
the second hypothesis was based on phylogenetic support that included analysis of 
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mitochondrial, ribosomal, and nuclear genes to investigate the relationship among 
the various C. neoformans and C. gattii genotypes. The different genotypes clustered in 
six monophyletic lineages for all loci studied, suggesting that C. neoformans serotype 
A and D represent two different species and that C. gattii genotypes represent four 
individual taxa [107, 108]. The third hypothesis goes a little further, considering that 
each genotype within C. neoformans and C. gattii has sufficient genotypic variation to 
be considered a different species [109].
Phenotypic diversity within the C. gattii species complex is also supporting the division 
of five species. Capsule and cell size showed to be variable within the complex, C. 
gattii s.s. (genotype AFLP4/VGI) had the largest capsules but smaller cells compared 
to the other species, while C. deuterogattii (genotype AFLP6/VGII) has the largest 
cells but smaller capsules [111]. All species in the C. gattii species complex have 
the ability to grow at 25, 30, and 35 °C, but with variable tolerance to 37 °C [1, 111]. 
Cryptococcus deuterogattii (genotype AFLP6/VGII) has the highest thermotolerance to 
37 °C, while C. gattii s.s. (genotype AFLP4/VGI), C. bacillisporus (genotype AFLP/VGIII), 
and C. tetragattii (genotype AFLP7/VGIV) have less growth at 37 °C than 30 °C [1, 111, 
112]. There is no significant difference in tolerance to oxidative or osmotic stresses 
among species [111, 112].
The understanding of genetic diversity is an important step for the discovery 
of previously unrecognized phenetic differences [111]. The exact moment that 
individuals in an ancestral species are split into progeny species is not recognized for 
any method of species delimitation, because this process needs time until the changes 
in morphology, mating behavior, or gene sequences may be recognized in the 
progeny species [113]. Phylogenomic analyses calculated the time since divergence of 
the C. neoformans species complex and the C. gattii species complex to be ~34 million 
years ago (mya) [114]; the divergence between C. deuterogattii (AFLP6/VGII) and the 
other species of the C. gattii species complex occurred ~12 mya [114, 115]; and the 
divergence of C. neoformans (AFLP1/VNI/AFLP1; VNII/AFLP1A/1B) and C. deneoformans 
(VNIV/AFLP2), ~24 mya [115]. The divergence among the species within the C. 
neoformans/C. gattii species complexes occurred recently and will most likely continue 
as an ongoing process. The occurrence of interspecies hybrids may also be attributed 
to the recent divergence event, because species currently hybridizing are most likely 
the youngest [116].
Although a revision of the cryptococcal taxonomy has been published, part of the 
cryptococcal research community is not fully in favor of using the ‘seven species 
recognition’. Some investigators believe that it will lead to taxonomic instability due 
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to the fact that there are most likely more species present. Many points have been 
discussed, including the number of isolates used, the use of phylogenetic approaches 
for species delineation, the accommodation of hybrids in the new taxonomy, and the 
fact that the new names may cause confusion between the published literature and 
clinical practice [110]. With these points of view, Kwon-Chung and colleagues (2017) 
suggested the use of the “C. neoformans species complex” and the “C. gattii species 
complex” as an intermediate step, instead of using the seven species nomenclature, 
until biological and clinically relevant differences become clear [110]. Although, 
according to Hagen and colleagues (2017), it is important to consider the presence of 
different species inside the complexes to avoid delay in the clinical progress [117].
Final remarks
Clinical and environmental occurrence of the C. gattii species complex is related to 
geographic location, which may be attributed to the (micro)climate, or even a lack 
of diagnosis/environmental isolation. Cryptococcosis in most developing countries 
is underreported and the precise burden of cryptococcosis caused by the C. gattii 
species complex is uncertain. In addition, not all clinical laboratories differentiate 
the pathogenic Cryptococcus species. In the environment, many tree species have 
been described as a reservoir, proving that the C. gattii species complex has no tree 
species-specific relation, and is widely spread in the environment.
Cryptococcus gattii species complex members differ in phenotypic traits, as 
capsule and cell size, thermotolerance and antifungal susceptibility. Many studies 
have demonstrated higher MICs of azoles for members of the C. gattii species 
complex compared to the C. neoformans species complex. Difference in antifungal 
susceptibility has also been observed within the C. gattii species complex, with C. 
deuterogattii (genotype AFLP6/VGII) being less susceptible to azoles than C. gattii 
s.s (genotype AFLP4/VGI). However, in vitro antifungal susceptibility does not 
correlate to in vivo susceptibility. Clinical manifestations in patients with C. gattii 
s.l. infections tend to be more severe than C. neoformans. In the former, cerebral 
involvement causes more hydrocephalus, focal CNS signs, as well as papilledema, 
ataxia, hearing loss, altered mentation, and neurological sequelae. Usually, 
meningoencephalitis caused by C. gattii s.l. is followed by higher intracranial 
pressures, sometimes irresponsible to multiple lumbar punture and/or CNF shunts. 
Simultaneous pulmonary involvement in >50% of patients is also observed, and 
mass lesions (cryptococcomas) are associated to a prolonged clinical course and 
respond slowly to therapy.
26
A new taxonomy of the polyphyletic genus Cryptococcus has been published, 
including the medical important species complexes C. neoformans and C. gattii. In 
addition, there are different opinions about the new classification. The presence 
of genetic differences within the C. gattii species complex needs to be considered 
in future studies to correlate genotypic and phenotypic traits of each species to 
diseases clinical presentation.
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Abstract
Cryptococcosis, caused by Cryptococcus gattii sensu lato, is an emerging disease 
that was initially found in (sub)tropical regions but recently expanded to temperate 
regions. Cryptococcus gattii s.l. infections are mostly encountered in healthy 
individuals, frequently affecting both lungs and the central nervous system (CNS). 
Usually, C. gattii s.l. is less susceptible to antifungal compounds than its counterpart, 
C. neoformans s.l. We studied 18 clinical C. gattii s.l. isolates with amplified fragment 
length polymorphism (AFLP) fingerprinting, mating-typing, multi-locus sequence 
typing (MLST) and antifungal susceptibility testing. All isolates were C. deuterogattii 
(genotype AFLP6/VGII), 14 were mating-type α and four were type a. Amphotericin 
B, itraconazole, voriconazole, posaconazole and isavuconazole showed high activity, 
with minimum inhibitory concentration (MIC) ranges of 0.063 – 0.25, 0.031 – 0.25, 
0.031 – 0.25, 0.031 – 0.25 and <0.016 – 0.25 μg mL−1, respectively. Fluconazole and 
flucytosine had high geometric mean MICs of 2.07 and 3.7 μg mL−1, respectively. 
Most cases occurred in immunocompetent patients (n = 10; 55.6 %) and CNS 
involvement was the most common clinical presentation (n = 14; 77.8 %). Three 
patients (16.7 %) showed sequelae, hyperreflexia, dysarthria, disdiadochokinesia, 
anosmia and upper limb weakness. In conclusion, all infections were caused by C. 
deuterogattii (AFLP6/VGII) and the majority of patients were immunocompetent, 
with the CNS as the most affected site. All antifungal drugs had high in vitro activity 
against C. deuterogattii isolates, except fluconazole and flucytosine.
Keywords: Cryptococcosis, Cryptococcus gattii, Cryptococcus deuterogattii, 





Cryptococcosis is caused by basidiomycetous yeast species that belong to the 
Cryptococcus gattii/Cryptococcus neoformans species complexes, mainly affecting 
lungs and the central nervous system (CNS) [1]. The taxonomy of the polyphyletic 
genus Cryptococcus has been thoroughly revised [2–4]. The two varieties of C. 
neoformans were recognised as species, with C. neoformans (=formerly C. neoformans 
variety grubii) and C. deneoformans (=formerly C. neoformans variety neoformans) 
[2]. The five C. gattii species complex genotypes were raised to the species level as 
C. gattii sensu stricto (AFLP4/VGI), C. bacillisporus (AFLP5/VGIII), C. deuterogattii 
(AFLP6/VGII), C. tetragattii (AFLP7/VGIV) and C. decagattii (AFLP10/VGIV) [2]. 
Cryptococcus gattii s.s. and C. deuterogattii are the main culprits of infections 
in immunocompetent hosts [2, 5], whereas C. bacillisporus, C. tetragattii and C. 
decagattii are commonly associated with immunocompromised hosts [2, 6–8]. 
Members of the C. gattii species complex have increasingly been reported 
from temperate climate regions [5, 9–11]. Trading of tree products, transport of 
propagules through water currents and via animals, insects and humans may be 
responsible for the world-wide spread [12, 13]. The first environmental isolation of 
C. gattii s.l. was reported from Eucalyptus camaldulensis [14]. Globally, C. gattii s.l. has 
been found on a plethora of other species of trees [13, 15–19]. 
In Europe, C. gattii s.s. is the most frequently encountered species, while few 
cases of C. deuterogattii infection are travel-related [20–22]. In Asia and Australia, 
C. gattii s.s. and C. deuterogattii are predominant [23]. Cryptococcus bacillisporus is 
rarely encountered outside North and South America [21, 23, 24], while C. tetragattii 
has mainly been isolated from Africa and India [8, 23]. On the American continent, 
C. deuterogattii is the predominant species among clinical and environmental 
isolates [23]. In North America, C. deuterogattii subgenotypes (AFLP6A/VGIIa, 
AFLP6B/VGIIb and AFLP6C/VGIIc) were reported as the cause of expanding 
outbreaks [5, 9, 10, 25]. A recent study showed that, by using coalescence gene 
genealogy analysis, the ancestral lineage of C. deuterogattii originated from South 
America, specifically from the Brazilian Amazon Rainforest, where mating-types a 
and α were reported in nearly equal rates, providing evidence of recombination 
within the Brazilian C. deuterogattii population [25]. 
Cryptococcus gattii s.l. is less susceptible to common antifungal compounds than 
C. neoformans; fluconazole and flucytosine show lower in vitro activity against 
C. deuterogattii strains [26–28]. In addition, heteroresistance to azoles in the 
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C. neoformans/C. gattii species complexes is an intrinsic mechanism that may 
contribute to relapse of cryptococcosis during maintenance therapy [29, 30]. 
In the present study, our aim was to compare the clinical outcome with molecular 
and antifungal susceptibility data of Brazilian C. gattii s.l. isolates.
Materials and methods
Isolates and clinical data
Eighteen clinical C. gattii s.l. isolates were isolated at the Hospital de Clínicas, 
Curitiba, PR, Brazil between 1999 and 2015. A single colony was taken for further 
microbiological and molecular characterisation. Medical records were accessed to 
collect clinical information.
Molecular characterisation
Extraction of genomic DNA, mating-type determination, amplified fragment length 
polymorphism (AFLP) fingerprinting and multi-locus sequence typing (MLST) were 
performed as described previously [20–22, 31]. 
Sequences were compared with those deposited in the MLST database (http://mlst.
mycologylab.org). The alignment was performed with the online MAFFT alignment 
module [32] and visual inspection by MEGA version 7 [33], followed by a 1000× 
bootstrapped maximum likelihood analysis on an MLST dataset that comprises all 
known C. deuterogattii sequence types [8].
Antifungal susceptibility testing
Broth microdilution testing [34] included amphotericin B (Bristol Myers Squibb, 
Munich, Germany), fluconazole (Pfizer, Sandwich, United Kingdom), itraconazole 
(Janssen Pharmaceutica, Beerse, Belgium), voriconazole (Pfizer), posaconazole 
(Merck, Kenilworth, NJ, USA), isavuconazole (Basilea Pharmaceutica, Basel, 
Switzerland) and flucytosine (ICN Pharmaceuticals, Zoetermeer, The Netherlands). 
The concentration ranges were 0.016 – 16 μg mL−1 for amphotericin B, itraconazole, 
voriconazole, posaconazole and isavuconazole, and 0.062 – 64 μg mL−1 for 
fluconazole and flucytosine. Cryptococcus isolates were cultured onto Sabouraud 
dextrose agar for 48 h at 30 °C and the inocula were adjusted to 1 × 103 CFU/mL in 
0.9 % NaCl to perform the test. The microdilution plates were incubated at 35 °C for 
72 h and the minimal inhibitory concentrations (MICs) were defined as the lowest 
concentration that produced complete growth inhibition for amphotericin B and 
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prominent decrease of growth (50 %) for other antifungal agents when compared 
with the drug-free growth control. Candida parapsilosis ATCC22019 and C. krusei 
ATCC6258 were used as quality controls [34]. The interpretation of MIC values was 
based on the epidemiological cut-off value (ECV) [26–28]. MIC50 and MIC90 values 
were obtained by ordering the data for each antifungal in ascending order and 
selecting the median and 90th quantile, respectively. Geometric mean MICs were 
calculated using Microsoft Office Excel 2010 software (Microsoft, Redmond, WA, 
USA). When the MIC was higher or less than the dilutions tested, 1 log2 dilution 
higher or 1 log2 dilution lower was used to calculate the geometric mean.
Results
Molecular characterisation
Mating-type analysis showed that 14 isolates were mating-type α and four were 
type a. MLST analysis showed that all 18 isolates clustered with the C. deuterogattii 
AFLP6/VGII reference strain WM178 (Fig. 1). Maximum likelihood analysis showed 
that most isolates were related with other Brazilian isolates, while isolate UFU986 
was genetically indistinguishable from the outbreak genotype AFLP6A/VGIIa 
(Fig. 1). MLST sequences were deposited in GenBank with the accession numbers 
KU642658–KU642671, KU642673–KU642676 (CAP59), KU642703–KU642716, 
KU642718–KU642721 (GPD1), KU642748–KU642761, KU642763–KU642766 (IGS1), 
KU642793–KU642806, KU642808–KU642811 (LAC1), KU642838–KU642851, 
KU642853–KU642856 (PLB1), KU642883–KU642896, KU642898–KU642901 (SOD1) 
and KU642928–KU642938, KU642940–KU652944, KU642946, KU642966 (URA5). By 
AFLP genotyping analysis, four isolates clustered together with the C. deuterogattii 
AFLP6/VGII reference strain WM178, while the remaining isolates clustered in two 
distinct clades due to the presence of several dominant markers (Fig. 2).
Antifungal susceptibility profiles
The MIC values are presented in Table 1. Itraconazole, voriconazole, posaconazole, 
isavuconazole and amphotericin B showed high activity against C. deuterogattii. 






























































































































































































































































































































































































































































































































































































































































































































Table 1. Minimal inhibitory concentrations (MICs) of all the Cryptococcus deuterogattii isolates 
studied
Isolate Code
Minimal Inhibitory Concentration (µg mL-1)
AMB FLC ITC VOR POS ISA 5FC
G3 0.063 0.5 0.063 0.063 0.063 0.031 4
G4 0.125 8 0.25 0.25 0.25 0.25 8
G6 0.031 8 0.125 0.125 0.125 0.063 2
G8 0.031 2 0.125 0.063 0.063 0.063 4
G10 0.125 4 0.125 0.125 0.125 0.125 8
G11 0.063 0.5 0.031 0.031 0.031 <0.016 1
G12 0.063 0.5 0.063 0.063 0.063 0.063 4
G13 0.031 4 0.063 0.063 0.063 0.063 2
G14 0.063 4 0.125 0.125 0.125 0.125 4
G15 0.125 4 0.125 0.125 0.125 0.125 4
G18 0.125 2 0.125 0.063 0.063 0.063 4
G19 0.125 16 0.25 0.25 0.25 0.25 4
N377 0.125 0.5 0.063 0.063 0.063 0.031 8
UFU303 0.125 8 0.125 0.125 0.125 0.063 4
UFU489 0.063 0.5 0.063 0.063 0.063 0.031 2
UFU675 0.125 0.5 0.063 0.063 0.063 0.063 4
UFU986 0.063 4 0.25 0.125 0.125 0.125 4
UFU993 0.125 1 0.063 0.063 0.063 0.063 4
MIC range 0.063-0.25 0.5-16 0.031-0.25 0.031-0.25 0.031-0.25 <0.016-0.25 1-8
MIC50 0.063 2 0.125 0.063 0.063 0.063 4
MIC90 0.125 8 0.25 0.125 0.125 0.125 8
Geometric mean 0.0788 2.0785 0.0994 0.0853 0.0853 0.0651 3.7034
AMB, amphotericin B; FLC, fluconazole; ITC, itraconazole; VOR, voriconazole; POS, posaconazole; ISA, 
isavuconazole; 5FC, flucytosine.
Clinical data
The majority of isolates were recovered from immunocompetent patients 
(n = 10; 55.6 %). Fourteen (77.8 %) had CNS involvement and four (22.2 %) of 
them were HIV-positive. Furthermore, six patients (33.3%) had lung infection, 
including five (27.7 %) with associated CNS symptoms, while two patients (11.1 %) 
had cutaneous cryptococcosis. Three (16.7 %) developed neurological sequelae 
after the cryptococcal infection, one left-sided hyperreflexia, dysarthria and 
disdiadochokinesia, one had motor sequelae in the upper limbs and one developed 
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anosmia. Nine patients (50 %) were treated with a combination of amphotericin B 
and fluconazole, one received amphotericin B and itraconazole, one amphotericin 
B and two were treated with isavuconazole. Two patients received liposomal 
amphotericin B after development of nephrotoxicity. Treatment dosing and 
outcome data are summarised in Fig. 2.
Discussion
Infections caused by members of the C. gattii species complex have a wide 
spectrum of clinical presentations, including pneumonia, meningoencephalitis, 
skin lesions and pulmonary and cerebral cryptococcoma formation, and surgical 
intervention may be necessary in certain cases [6, 35–38]. CNS disease is associated 
with neurological sequelae such as visual impairment, deafness, limb weakness and 
dysphasia [39]. We observed hyperreflexia, dysarthria, disdiadochokinesia, anosmia 
and upper limb weakness. Some studies reported that 60–90% of patients with C. 
gattii species complex cryptococcosis have pulmonary symptoms with or without 
CNS involvement [10, 39, 40]. These data differ from this study, where the majority 
of patients (n = 14; 77.8 %) had CNS disease, five (27.7 %) also had lung involvement 
and a solitary patient (5.5 %) had only a lung infection. 
All isolates were found to be C. deuterogattii, which is in concordance with the 
literature data, as it is predominant among clinical, veterinary and environmental 
isolates in Brazil [18, 41–50]. Cryptococcus gattii s.s. is more often reported in 
southern Brazil [51, 52] and the southeastern region [52, 53], and C. bacillisporus 
in the southeastern and northeastern part [52]. Despite increasing epidemiological 
surveys in Brazil, information about the species distribution are fragmented and 
underrepresented from several Brazilian states. This is mainly due to the lack of 
proper diagnosis and the absence of an efficient reporting system [43]. 
We found that four out of 18 C. deuterogattii were mating-type a. The presence 
of both mating types within the South American C. deuterogattii population 
demonstrates that recombination events are a common phenomenon, causing high 
genetic diversity compared to other localities [25]. Globally, the majority of clinical 
isolates were found to be mating-type α, and with respect to C. deuterogattii, this 
is also the case for the ongoing outbreaks in North America [6, 25]. Recently, the 
first Australian C. deuterogattii mating-type a isolate was reported [54]. The absence 
or low number of mating-type a isolates within study populations suggests that C. 
deuterogattii is either clonal or reproduces by same-sex mating [55]. 
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Antifungal susceptibility testing showed that amphotericin B had high activity, 
which is in concordance with other studies [27, 48, 56–58]. Fluconazole had the 
lowest activity among the triazoles tested, with an MIC range of 0.5 – 16 μg mL−1. 
Nevertheless, all MIC values were in the susceptible range [26, 59]. Hagen et al. [58] 
observed lower fluconazole activity against all C. gattii species complex members, 
with European and North American isolates showing higher MIC values (0.125 to 
>64 μg mL−1 and 0.5 – 64 μg mL−1, respectively). A recent Brazilian study reported 
high MICs (2 – 64 μg mL−1), with a geometric mean of 6.08 μg mL−1 for C. deuterogattii 
[60]. We also observed low MICs of itraconazole and new triazoles [26, 27, 56, 58]. 
Isavuconazole is a second-generation triazole antifungal, with a broad spectrum of 
activity against many important fungal pathogens [61]. Antifungal susceptibility 
tests have shown potent in vitro activity against members of C. neoformans/C. gattii 
species complexes, even for those that are less susceptible to fluconazole [28, 62, 
63]. We observed that isavuconazole had excellent activity against C. deuterogattii, 
showing the lowest geometric mean MIC (0.065 μg mL−1) among the antifungal 
compounds tested. Two immunocompetent female patients were included in 
a multi-centre international clinical trial with isavuconazole (ClinicalTrials.gov, 
NCT00634049) [64]. The first was 20 years old and working in a supermarket, where 
she had continuous contact with wood, fruits and vegetables. After the diagnosis, 
she received amphotericin B deoxycholate therapy for 16 days, but without 
response. The therapy was switched to isavuconazole, resulting in a complete 
clinical, radiological and microbiological response after 6 months of treatment. 
Anosmia was observed as a sequel. The second patient was a pharmacist, who 
received isavuconazole as primary therapy for a total of 176 days, resulting in a 
complete response without any sequelae. 
Flucytosine had the lowest in vitro activity, showing the highest geometric mean 
MIC (3.7 μg mL−1) among the antifungals tested, but the MICs for all isolates were 
within the wild-type range. It is known that resistance to flucytosine is rare [58, 
65], but the use as monotherapy could lead to acquired resistance [66]. There are 
studies showing less susceptibility to flucytosine in Cryptococcus [58, 67, 68], but 
since flucytosine is not registered in Brazil, we supposed that the patients did not 
receive previous treatment with this drug. Higher MICs of flucytosine were also 
reported in other Brazilian studies [45, 48, 53, 60]. 
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In conclusion, the majority of cases occurred in immunocompetent patients, with 
the CNS as the most affected site. All infections were caused by C. deuterogattii 
(AFLP6/VGII) and all antifungal drugs had in vitro activity against this species, 
except fluconazole and flucytosine.
Acknowledgments 
The work of Patricia Fernanda Herkert was financially supported by ‘Coordenação 
de Aperfeiçoamento de Pessoal de Nível Superior’ and ‘Conselho Nacional de 
Desenvolvimento Científico e Tecnológico’, Brazil.
Conflict of interest 
JFM served as a consultant to and has received research grants from Astellas, Basilea, 
Gilead Sciences and Merck. All of the other authors declare no conflicts of interest.
46
References
1. Kwon-Chung KJ, Fraser JA, Doering TL, Wang Z, Janbon G, Idnurm A, et al. Cryptococcus neoformans 
and Cryptococcus gattii, the etiologic agents of cryptococcosis. Cold Spring Harb Perspect Med. 
2014;4(7):a019760.
2. Hagen F, Khayhan K, Theelen B, Kolecka A, Polacheck I, Sionov E, et al. Recognition of seven species in 
the Cryptococcus gattii/Cryptococcus neoformans species complex. Fungal Genet Biol. 2015;78:16–48.
3. Liu X-Z, Wang Q-M, Göker M, Groenewald M, Kachalkin AV, Lumbsch HT, et al. Towards an integrated 
phylogenetic classification of the Tremellomycetes. Stud Mycol. 2015;81:85–147.
4. Liu X-Z, Wang Q-M, Theelen B, Groenewald M, Bai F-Y, Boekhout T. Phylogeny of tremellomycetous 
yeasts and related dimorphic and filamentous basidiomycetes reconstructed from multiple gene 
sequence analyses. Stud Mycol. 2015;81:1–26.
5. Kidd SE, Hagen F, Tscharke RL, Huynh M, Bartlett KH, Fyfe M, et al. A rare genotype of Cryptococcus 
gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). PNAS. 
2004;101(49):17258–63.
6. Byrnes EJ, Bartlett KH, Perfect JR, Heitman J. Cryptococcus gattii: an emerging fungal pathogen 
infecting humans and animals. Microbes Infect. 2011;13(11):895–907.
7. Springer DJ, Billmyre RB, Filler EE, Voelz K, Pursall R, Mieczkowski PA, et al. Cryptococcus gattii VGIII 
isolates causing infections in HIV/AIDS patients in Southern California: identification of the local 
environmental source as arboreal. PLoS Pathog. 2014;10(8):e1004285.
8. Nyazika TK, Hagen F, Meis JF, Robertson VJ. Cryptococcus tetragattii as a major cause of cryptococcal 
meningitis among HIV-infected individuals in Harare, Zimbabwe. J Infect. 2016;72(6):745–52.
9. Datta K, Bartlett KH, Baer R, Byrnes E, Galanis E, Heitman J, et al. Spread of Cryptococcus gattii into 
Pacific Northwest Region of the United States. Emerg Infect Dis. 2009;15(8):1185–91.
10. Galanis E, MacDougall L, Kidd S, Morshed M, the British Columbia Cryptococcus gattii working 
group. Epidemiology of Cryptococcus gattii, British Columbia, Canada, 1999–2007. Emerg Infect Dis. 
2010;16(2):251–7.
11. Hagen F, Boekhout T. The Search for the Natural Habitat of Cryptococcus gattii. Mycopathologia. 
2010;170(4):209–11.
12. Kidd SE, Chow Y, Mak S, Bach PJ, Chen H, Hingston AO, et al. Characterization of environmental sources 
of the human and animal pathogen Cryptococcus gattii in British Columbia, Canada, and the Pacific 
Northwest of the United States. Appl Environ Microbiol. 2007;73(5):1433–43.
13. Springer DJ, Chaturvedi V. Projecting global occurrence of Cryptococcus gattii. Emerg Infect Dis. 
2010;16(1):14–20.
14. Ellis DH, Pfeiffer TJ. Natural habitat of Cryptococcus neoformans var. gattii. J Clin Microbiol. 
1990;28(7):1642–4.
15. Kidd SE, Bach PJ, Hingston AO, Mak S, Chow Y, MacDougall L, et al. Cryptococcus gattii dispersal 
mechanisms, British Columbia, Canada. Emerg Infect Dis. 2007;13(1):51–7.
16. Chowdhary A, Randhawa HS, Prakash A, Meis JF. Environmental prevalence of Cryptococcus neoformans 
and Cryptococcus gattii in India: An update. Crit Rev Microbiol. 2012;38(1):1–16.
17. Hagen F, Chowdhary A, Prakash A, Yntema J-B, Meis JF. Molecular characterization of Cryptococcus 
gattii genotype AFLP6/VGII isolated from woody debris of divi-divi (Caesalpinia coriaria), Bonaire, 
Dutch Caribbean. Rev Iberoam Micol. 2014;31(3):193–6.
18. Anzai MC, Lazéra M dos S, Wanke B, Trilles L, Dutra V, de Paula DAJ, et al. Cryptococcus gattii VGII in a 
Plathymenia reticulata hollow in Cuiabá, Mato Grosso, Brazil. Mycoses. 2014;57(7):414–8.
19. Linares C, Colom MF, Torreblanca M, Esteban V, Romera Á, Hagen F. Environmental sampling of 
Ceratonia siliqua (carob) trees in Spain reveals the presence of the rare Cryptococcus gattii genotype 
AFLP7/VGIV. Rev Iberoam Micol. 2015;32(4):269–72.
47
3
20. Hagen F, van Assen S, Luijckx GJ, Boekhout T, Kampinga GA. Activated dormant Cryptococcus gattii 
infection in a Dutch tourist who visited Vancouver Island (Canada): a molecular epidemiological 
approach. Med Mycol. 2010;48(3):528–31.
21. Hagen F, Colom MF, Swinne D, Tintelnot K, Iatta R, Montagna MT, et al. Autochthonous and dormant 
Cryptococcus gattii infections in Europe. Emerg Infect Dis. 2012;18(10):1618–24.
22. Colom MF, Hagen F, Gonzalez A, Mellado A, Morera N, Linares C, et al. Ceratonia siliqua (carob) trees as 
natural habitat and source of infection by Cryptococcus gattii in the Mediterranean environment. Med 
Mycol. 2012;50(1):67–73.
23. Cogliati M. Global Molecular epidemiology of Cryptococcus neoformans and Cryptococcus gattii: an 
atlas of the molecular types. Scientifica. 2013;2013:1–23.
24. Chowdhary A, Prakash A, Randhawa HS, Kathuria S, Hagen F, Klaassen CH, et al. First environmental 
isolation of Cryptococcus gattii, genotype AFLP5, from India and a global review: Cryptococcus gattii, 
genotype AFLP5, from India. Mycoses. 2013;56(3):222–8.
25. Hagen F, Ceresini PC, Polacheck I, Ma H, Nieuwerburgh F van, Gabaldón T, et al. Ancient dispersal of the 
human fungal pathogen Cryptococcus gattii from the Amazon Rainforest. PLoS ONE. 2013;8(8):e71148.
26. Espinel-Ingroff A, Aller AI, Canton E, Castanon-Olivares LR, Chowdhary A, Cordoba S, et al. Cryptococcus 
neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility 
endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, 
and voriconazole. Antimicrob Agents Chemother. 2012;56(11):5898–906.
27. Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, Fothergill A, Fuller J, Hagen F, et al. Cryptococcus 
neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility 
endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. 
Antimicrob Agents Chemother. 2012;56(6):3107–13. 
28. Espinel-Ingroff A, Chowdhary A, Gonzalez GM, Guinea J, Hagen F, Meis JF, et al. Multicenter study of 
isavuconazole MIC distributions and epidemiological cutoff values for the Cryptococcus neoformans-
Cryptococcus gattii species complex using the CLSI M27-A3 broth microdilution method: TABLE 1. 
Antimicrob Agents Chemother. 2015;59(1):666–8.
29. Sionov E, Chang YC, Garraffo HM, Kwon-Chung KJ. Heteroresistance to fluconazole in Cryptococcus 
neoformans is intrinsic and associated with virulence. Antimicrob Agents Chemother. 2009;53(7):2804–
15.
30. Varma A, Kwon-Chung KJ. Heteroresistance of Cryptococcus gattii to fluconazole. Antimicrob Agents 
Chemother. 2010;54(6):2303–11.
31. Illnait-Zaragozí MT, Martínez-Machín GF, Fernández-Andreu CM, Perurena-Lancha MR, Theelen B, 
Boekhout T, et al. Environmental isolation and characterisation of Cryptococcus species from living trees 
in Havana city, Cuba: Cryptococcus species from living trees, Cuba. Mycoses. 2012;55(3):e138–44.
32. Katoh K, Misawa K, Kuma K, Miyata T. MAFFT: a novel method for rapid multiple sequence alignment 
based on fast Fourier transform. Nucleic Acids Res. 2002;30(14):3059–66.
33. Kumar S, Stecher G, Tamura K. MEGA7: Molecular evolutionary genetics analysis version 7.0 for bigger 
datasets. Mol Biol Evol. 2016;33(7):1870–4.
34. Clinical and Laboratory Standards Institute (CLSI) (2008) Reference method for broth dilution antifungal 
susceptibility testing of yeasts; Approved standard—Third edition. CLSI document M27-A3 (ISBN 
1-56238-666-2). Clinical and Laboratory Standards Institute, 940 West Valley Road, Suite 1400, Wayne, 
Pennsylvania 19087-1898, USA
35. Marques SA, Bastazini I, Martins ALGP, Barreto JA, Barbieri D’Elia MP, Lastória JC, et al. Primary 
cutaneous cryptococcosis in Brazil: report of 11 cases in immunocompetent and immunosuppressed 
patients: Primary cutaneous cryptococcosis. Int J Dermatol. 2012;51(7):780–4.
36. Cicora F, Petroni J, Formosa P, Roberti J. A rare case of Cryptococcus gattii pneumonia in a renal 
transplant patient. Transpl Infect Dis. 2015;17(3):463–6.
48
37. Franco-Paredes C, Womack T, Bohlmeyer T, Sellers B, Hays A, Patel K, et al. Management of Cryptococcus 
gattii meningoencephalitis. Lancet Infect Dis. 2015;15(3):348–55.
38. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines 
for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of 
America. Clin Infect Dis. 2010;50(3):291–322.
39. Chen SC-A, Slavin MA, Heath CH, Playford EG, Byth K, Marriott D, et al. Clinical Manifestations of 
Cryptococcus gattii infection: determinants of neurological sequelae and death. Clin Infect Dis. 
2012;55(6):789–98.
40. Chen SC-A, Korman TM, Slavin MA, Marriott D, Byth K, Bak N, et al. Antifungal therapy and management 
of complications of cryptococcosis due to Cryptococcus gattii. Clin Infect Dis. 2013;57(4):543–51.
41. Santos WRA dos, Meyer W, Wanke B, Costa SPSE, Trilles L, Nascimento JLM do, et al. Primary endemic 
Cryptococcosis gattii by molecular type VGII in the state of Pará, Brazil. Mem Inst Oswaldo Cruz. 
2008;103(8):813–8.
42. Costa S do PSE, Lazéra M dos S, Santos WRA, Morales BP, Bezerra CCF, Nishikawa MM, et al. First isolation 
of Cryptococcus gattii molecular type VGII and Cryptococcus neoformans molecular type VNI from 
environmental sources in the city of Belém, Pará, Brazil. Mem Inst Oswaldo Cruz. 2009;104(4):662–4.
43. Martins LMS, Wanke B, Lazéra M dos S, Trilles L, Barbosa GG, Macedo RCL de, et al. Genotypes of 
Cryptococcus neoformans and Cryptococcus gattii as agents of endemic cryptococcosis in Teresina, 
Piauí (northeastern Brazil). Mem Inst Oswaldo Cruz. 2011;106(6):725–30.
44. Freire AKL, dos Santos Bentes A, de Lima Sampaio I, Matsuura ABJ, Ogusku MM, Salem JI, et al. 
Molecular characterisation of the causative agents of cryptococcosis in patients of a tertiary healthcare 
facility in the state of Amazonas-Brazil: Cryptococcosis in the state of Amazonas-Brazil. Mycoses. 
2012;55(3):e145–50.
45. Matos CS, de Souza Andrade A, Oliveira NS, Barros TF. Microbiological characteristics of clinical 
isolates of Cryptococcus spp. in Bahia, Brazil: molecular types and antifungal susceptibilities. Eur J Clin 
Microbiol Infect Dis. 2012;31(7):1647–52.
46. Silva DC, Martins MA, Szeszs MW, Bonfietti LX, Matos D, Melhem MSC. Susceptibility to antifungal 
agents and genotypes of Brazilian clinical and environmental Cryptococcus gattii strains. Diagn 
Microbiol Infect Dis. 2012;72(4):332–9.
47. Cardoso PHM, Baroni F de A, Silva EG, Nascimento DC, Martins MDA, Szezs W, et al. Feline nasal 
granuloma due to Cryptoccocus gattii type VGII. Mycopathologia. 2013;176(3–4):303–7.
48. Favalessa OC, De Paula DAJ, Dutra V, Nakazato L, Tadano T, Lazera M dos S, et al. Molecular typing and 
in vitro antifungal susceptibility of Cryptococcus spp from patients in Midwest Brazil. J Infect Dev Ctries 
[Internet]. 2014 [cited 2017 Sep 17];8(08). Available from: http://www.jidc.org/index.php/journal/
article/view/4446
49. Brito-Santos F, Barbosa GG, Trilles L, Nishikawa MM, Wanke B, Meyer W, et al. Environmental isolation 
of Cryptococcus gattii VGII from indoor dust from typical wooden houses in the deep Amazonas of the 
Rio Negro Basin. PLOS ONE. 2015;10(2):e0115866.
50. Headley SA, Di Santis GW, de Alcântara BK, Costa TC, da Silva EO, Pretto-Giordano LG, et al. Cryptococcus 
gattii-induced infections in dogs from Southern Brazil. Mycopathologia. 2015;180(3–4):265–75. 
51. Abegg MA, Cella FL, Faganello J, Valente P, Schrank A, Vainstein MH. Cryptococcus neoformans and 
Cryptococcus gattii isolated from the excreta of psittaciformes in a Southern Brazilian Zoological 
Garden. Mycopathologia. 2006;161(2):83–91.
52. Trilles L, Lazéra M dos S, Wanke B, Oliveira RV, Barbosa GG, Nishikawa MM, et al. Regional pattern of the 
molecular types of Cryptococcus neoformans and Cryptococcus gattii in Brazil. Mem Inst Oswaldo Cruz. 
2008;103(5):455–62.
53. Nascimento E, Bonifácio da Silva MEN, Martinez R, von Zeska Kress MR. Primary cutaneous 
cryptococcosis in an immunocompetent patient due to Cryptococcus gattii molecular type VGI in 
Brazil: a case report and review of literature. Mycoses. 2014;57(7):442–7.
49
3
54. Carriconde F, Gilgado F, Arthur I, Ellis D, Malik R, van de Wiele N, et al. Clonality and α-a recombination 
in the Australian Cryptococcus gattii VGII population - an emerging outbreak in Australia. PLoS One 
[Internet]. 2011;6(2). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3044715/
55. Fraser JA, Giles SS, Wenink EC, Geunes-Boyer SG, Wright JR, Diezmann S, et al. Same-sex mating and 
the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature. 2005 Oct;437(7063):1360–4.
56. Iqbal N, DeBess EE, Wohrle R, Sun B, Nett RJ, Ahlquist AM, et al. Correlation of genotype and in vitro 
susceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States. J Clin 
Microbiol. 2010;48(2):539–44.
57. Pasa CR, Chang MR, Hans-Filho G. Post-trauma primary cutaneous cryptococcosis in an 
immunocompetent host by Cryptococcus gattii VGII. Mycoses. 2012;55(2):e1-3.
58. Hagen F, Illnait-Zaragozi M-T, Bartlett KH, Swinne D, Geertsen E, Klaassen CHW, et al. In vitro antifungal 
susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 
350 clinical, veterinary, and environmental Cryptococcus gattii isolates. Antimicrob Agents Chemother. 
2010;54(12):5139–45.
59. Lockhart SR, Iqbal N, Bolden CB, DeBess EE, Marsden-Haug N, Worhle R, et al. Epidemiologic cutoff 
values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility. 
Diagn Microbiol Infect Dis. 2012;73(2):144–8.
60. Trilles L, Meyer W, Wanke B, Guarro J, Lazéra M. Correlation of antifungal susceptibility and molecular 
type within the Cryptococcus neoformans/C. gattii species complex. Med Mycol. 2012;50(3):328–32.
61. Miceli MH, Kauffman CA. Isavuconazole: a new broad-spectrum triazole antifungal agent. Clin Infect 
Dis. 2015;61(10):1558–65.
62. Illnait-Zaragozi M-T, Martínez GF, Curfs-Breuker I, Fernández CM, Boekhout T, Meis JF. In vitro activity 
of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 
Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother. 2008;52(4):1580–2.
63. Datta K, Rhee P, Byrnes E, Garcia-Effron G, Perlin DS, Staab JF, et al. Isavuconazole activity against 
Aspergillus lentulus, Neosartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with 
reduced azole susceptibility. J Clin Microbiol. 2013;51(9):3090–3.
64. Thompson GR, Rendon A, Ribeiro Dos Santos R, Queiroz-Telles F, Ostrosky-Zeichner L, Azie N, et al. 
Isavuconazole treatment of cryptococcosis and dimorphic mycoses. Clin Infect Dis. 2016;63(3):356–62.
65. Chen SC-A, Meyer W, Sorrell TC. Cryptococcus gattii infections. Clin Microbiol Rev. 2014;27(4):980–1024.
66. Hospenthal DR, Bennett JE. Flucytosine monotherapy for cryptococcosis. Clin Infect Dis. 
1998;27(2):260–4.
67. Illnait-Zaragozí MT, Martínez-Machín GF, Fernández-Andreu CM, Hagen F, Boekhout T, Klaassen CHW, 
et al. Microsatellite typing and susceptibilities of serial Cryptococcus neoformans isolates from Cuban 
patients with recurrent cryptococcal meningitis. BMC Infect Dis. 2010;10:289.
68. Chowdhary A, Randhawa HS, Sundar G, Kathuria S, Prakash A, Khan Z, et al. In vitro antifungal 
susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus 






Differential in vitro cytokine 
induction by the species of 
Cryptococcus gattii complex
Patricia F. Herkert,a,b,c Jessica C. dos Santos,d,e,f Ferry Hagen,g Fatima Ribeiro-Dias,d 
Flávio Queiroz-Telles,h Mihai G. Netea,e,f,i Jacques F. Meis,b,j Leo A. B. Joostend,e,f
aPostgraduate Program in Microbiology, Parasitology and Pathology, Biological Sciences, 
Department of Basic Pathology, Federal University of Paraná, Curitiba, Brazil; bDepartment of 
Medical Microbiology and Infectious Diseases, Canisius-Wilhelmina Hospital (CWZ), Nijmegen, 
the Netherlands; cCAPES Foundation, Ministry of Education of Brazil, Brasília, Brazil; dInstituto de 
Patologia Tropical e Saúde Pública, Universidade Federal de Goiás, Goiânia, Brazil; eDepartment 
of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands; fRadboud 
Center of Infectious Diseases (RCI), Radboud University Medical Center, Nijmegen, the 
Netherlands; gDepartment of Medical Mycology, Westerdijk Fungal Biodiversity Institute, Utrecht, 
the Netherlands; hCommunitarian Health Department, Hospital de Clínicas, Federal University 
of Parana, Curitiba, Brazil; iHuman Genomics Laboratory, Craiova University of Medicine and 
Pharmacy, Craiova, Romania; jCentre of Expertise in Mycology Radboudumc/CWZ, Nijmegen, the 
Netherlands
Published in: Infect Immun. 2018; 86(4):e00958-17
52
Abstract
Cryptococcal species vary in capsule and cell size, thermotolerance, geographic 
distribution, and affected populations. Cryptococcus gattii sensu stricto and 
C. deuterogattii affect mainly immunocompetent hosts; however, C. bacillisporus, 
C. decagattii, and C. tetragattii cause infections mainly in immunocompromised 
hosts. This study aimed to compare the capacities of different species of the C. 
gattii species complex to induce cytokines and antimicrobial molecules in human 
peripheral blood mononuclear cells (PBMCs). Cryptococcus bacillisporus and C. 
deuterogattii induced the lowest levels of tumor necrosis factor alpha (TNF-α), 
interleukin-1β (IL-1β), and IL-6 among the five species of the C. gattii complex. 
Cryptococcus deuterogattii induced higher levels of IL-22 than those induced by C. 
tetragattii and the environmental species C. flavescens. In addition, C. bacillisporus 
and C. gattii sensu stricto proliferated inside human monocyte-derived macrophages 
after 24 h of infection. All Cryptococcus species were able to generate reactive 
oxygen species (ROS) in human PBMCs, with C. bacillisporus and C. deuterogattii 
being more efficient than the other species. In conclusion, C. bacillisporus and C. 
deuterogattii induce lower levels of the proinflammatory cytokines TNF-α, IL-1β, 
and IL-6 and higher ROS levels than those induced by the other species. Species of 
the Cryptococcus gattii complex have different abilities to induce cytokine and ROS 
production by human PBMCs.





Cryptococcosis is a systemic fungal disease caused by the basidiomycetous 
yeasts belonging to the Cryptococcus neoformans/C. gattii species complexes [1]. 
The infection is acquired from the environment by inhalation of desiccated yeast 
cells or basidiospores, which establish either an asymptomatic latent infection or 
pneumonia and meningoencephalitis [2]. The taxonomy of the polyphyletic genus 
Cryptococcus was recently revised [1, 3, 4]. The two C. neoformans varieties were 
raised to the species level, as C. neoformans sensu stricto (formerly C. neoformans 
var. grubii) and C. deneoformans (formerly C. neoformans var. neoformans) [1]. In 
addition, the five genotypes within the C. gattii species complex were raised to the 
species level, as C. gattii sensu stricto (AFLP4/VGI), C. bacillisporus (AFLP5/VGIII), C. 
deuterogattii (AFLP6/VGII), C. tetragattii (AFLP7/VGIV), and C. decagattii (AFLP10/
VGIV) [1]. Although the taxonomic revision was established after >15 years of 
debate, part of the community prefers the use of the term “species complex” [5] 
despite the accumulating evidence for the revised taxonomy [6].
Species discrimination has clinical and epidemiological importance, as it 
has been observed that there are differences in disease presentation and in 
susceptibility profiles for antifungal drugs [1]. Infections by members of the 
C. gattii species complex mainly cause pneumonia, meningoencephalitis, 
skin lesions, pulmonary or cerebral cryptococcomas, and central nervous 
system (CNS) disease associated with neurological sequelae. These infections 
typically require prolonged antifungal therapy [7-11]. In contrast, severe 
meningitis is the main infection caused by C. neoformans sensu lato [12]. In 
addition, the species C. gattii sensu stricto and C. deuterogattii affect mainly 
immunocompetent hosts [1, 13], whereas C. bacillisporus, C. decagattii, and 
C. tetragattii are more commonly found in immunocompromised hosts, mostly 
HIV/AIDS patients, similar to C. neoformans sensu lato [1, 7, 14, 15]. However, fatal 
cryptococcosis by C. bacillisporus in immunocompetent hosts has been reported in 
the literature [16, 17].
In addition, phenotypic diversity supports the differences among the species 
within the C. gattii species complex. Capsule and cell sizes vary: C. gattii sensu stricto 
(AFLP4/VGI) has the largest capsules but smaller cells than those of other species, 
whereas C. deuterogattii (AFLP6/VGII) has the largest cells but smaller capsules [18]. 
All species have the ability to grow at 25, 30, and 35°C, but they have various levels 
of tolerance to 37°C [1, 18]. Cryptococcus deuterogattii (AFLP6/VGII) has the highest 
thermotolerance at 37°C, while C. gattii sensu stricto (AFLP4/VGI), C. bacillisporus 
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(AFLP/VGIII), and C. tetragattii (AFLP7/VGIV) have less growth at 37°C than at 30°C [1, 
18, 19]. There are no significant differences in tolerance to oxidative [19] or osmotic 
[18] stresses among species.
An important aspect of cryptococcal infections is how Cryptococcus species evade 
the host immune system and establish infection. To reach the CNS, cryptococcal 
cells use paracytosis to move between tight junctions of the brain endothelium [20], 
transcytosis to move directly through the endothelial cells [21], and hitchhiking 
within phagocytes [22, 23]. Typically, these fungi avoid killing by host phagocytic 
cells due to virulence factors, such as the polysaccharide capsule, melanin, 
and urease production, in addition to other traits, such as the ability to escape 
phagocytosis by inducing nonlytic exocytosis and by producing titan cells [24-26].
Cryptococcus gattii sensu lato is also able to disturb the inflammatory process, 
inducing low levels of proinflammatory cytokine tumor necrosis factor 
alpha (TNF-α) production in vitro [27]. The cryptococcal capsule components 
glucuronoxylomannan and galactoxylomannan dampen inflammation by 
suppressing the NF-κB pathway and locking surface antigen recognition [27, 28]. 
In consequence, dendritic cell maturation is compromised, leading to release 
of TNF-α, interleukin-12 (IL-12), and IL-23 at low levels and to decreased major 
histocompatibility complex class II molecule expression. Thus, suboptimal T-cell 
responses and weak proinflammatory responses are induced, inhibiting adequate 
cryptococcal clearance [27-29].
Most knowledge about the immune response patterns against Cryptococcus species 
is derived from studies of C. neoformans species complex isolates performed 
with animal models and human cells [30-34]. However, the interest in studying 
immune response patterns against the members of the C. gattii species complex 
has increased recently [28, 29, 35-38] due to evidence of genetic diversity, phenetic 
differences, and epidemiologic particularities among the species [1, 18, 39-41]. 
Based on these aspects, the present study hypothesized that the five species within 
the C. gattii complex have different abilities to induce cytokine production in human 
cells, a crucial step for the activation of host defense. In addition, macrophage 
infection and antimicrobial molecules were evaluated.
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Fig 1. Monocyte-derived cytokine production induced by members of the C. gattii species complex. 
Human PBMCs (n = 6) from healthy volunteers (5 × 105 cells/ml) were stimulated with LPS (10 ng/ml) 
or live yeast forms of Cryptococcus species (2.5 × 106 cells/ml). After 24 h of incubation, TNF-α, IL-1α, 
IL-1β, IL-6, IL-8, and IL-10 production in supernatants was determined by ELISA. Mean values with 
SEM for three independent experiments done in duplicate are presented. *, P ≥ 0.05; **, P ≥ 0.01; ***, 
P ≥ 0.001. s.s., sensu stricto.
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Results
Cryptococcus bacillisporus and C. deuterogattii induced lower levels of 
TNF-α, IL-1β, and IL-6 than those induced by the other species
The quantitative concentrations of cytokines produced by human peripheral blood 
mononuclear cells (PBMCs) from healthy volunteers after stimulation with different 
Cryptococcus species are shown in Fig. 1. Cryptococcus neoformans sensu stricto, 
C. bacillisporus, and C. deuterogattii induced lower levels of the proinflammatory 
cytokines TNF-α, IL-1β, and IL-6 than those induced by the other species. 
Cryptococcus gattii sensu stricto and the control species C. flavescens induced higher 
levels of IL-10 than those observed with the other species, and no differences in IL-8 
levels were observed.
Cryptococcus deuterogattii induced higher levels of IL-22 than those 
induced by C. tetragattii and C. flavescens 
A comparison of quantitative T-cell-derived cytokine production stimulated by 
Cryptococcus species is shown in Fig. 2. Cryptococcus species induced low levels 
of gamma interferon (IFN-γ) production by human PBMCs, without significant 
differences among the species. The same was observed for IL-17, with all species 
tested inducing small amounts of IL-17. For IL-22, C. bacillisporus, C. decagattii, 
C. deuterogattii, and C. gattii sensu stricto induced similar levels. However, C. 
deuterogattii induced higher levels than those induced by C. tetragattii (P ≥ 0.01) 
and C. flavescens (P ≥ 0.01).
Cryptococcus bacillisporus and C. gattii sensu stricto proliferated inside 
macrophages after 24 h of infection 
Human primary granulocyte-macrophage colony stimulating factor (GM-CSF)-
derived macrophages were used to evaluate the rates of phagocytosis of three 
Cryptococcus species. Cryptococcus neoformans sensu stricto was included as a control; 
C. bacillisporus and C. gattii sensu stricto were included because the first induced low 
and the latter large amounts of proinflammatory cytokines. The rates of phagocytosis 
for macrophages infected with C. neoformans sensu stricto, C. bacillisporus, and 
C. gattii sensu stricto are shown in Fig. 3. After infection, 60 to 80% of the total number 
of macrophages were infected with cryptococci. No significant differences in the 
percentage of infection were observed after 3 or 24 h of incubation. After preactivation 
of macrophages with IFN-γ (50 U/ml), no effect on phagocytosis rates was observed 
(Fig. 3A), and no differences in numbers of intracellular cryptococci per preactivated 
or nonpreactivated macrophage were found. However, after 24 h, there was a 
significant increase in the number of intracellular C. neoformans, C. bacillisporus, or 
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C. gattii sensu stricto organisms per macrophage (P ≥ 0.05), independent of the 
absence or presence of IFN-γ. The infection index after 24 h was lower for C. gattii 
sensu stricto (P ≥ 0.05) than for C. neoformans and C. bacillisporus in preactivated and 
nonpreactivated macrophages. Photomicrographs of macrophages infected with 
different cryptococcal species are presented in Fig. 3B to D.
Fig 2. T-cell-derived cytokine production induced by members of the C. gattii species complex. 
Human PBMCs (n = 6) from healthy volunteers (5 × 105 cells/ml) were stimulated with LPS (10 ng/
ml), live yeast forms of Cryptococcus species (2.5 × 105 cells/ml), or heat-killed Candida albicans (1 
× 107 cells/ml), as a positive control. After 7 days of incubation, IL-17, IL-22, and IFN-γ production 
in supernatants was determined by ELISA. Mean values (n = 6) with SEM for three independent 
experiments done in duplicate are presented. *, P ≥ 0.05; **, P ≥ 0.01. ^, Candida albicans.
The phagocytosed cryptococci were recovered by macrophage lysis, and their 
viability was investigated by CFU counting (Fig. 3E). The numbers of viable 
Cryptococcus neoformans sensu stricto and C. bacillisporus organisms were higher 
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after 24 h than after 3 h of infection for nonpreactivated macrophages. For 
preactivated macrophages, there was an increase in the number of viable cells only 
for C. bacillisporus after 24 h of infection compared to 3 h of infection. In contrast, C. 
gattii sensu stricto had more viability than that of C. bacillisporus 3 h after infecting 
nonpreactivated macrophages. Nevertheless, the viability of C. gattii sensu stricto 
decreased from 3 h to 24 h. Comparing the viabilities among species, C. neoformans 
had more viability than C. bacillisporus and C. gattii sensu stricto after 24 h of 
infection in preactivated or nonpreactivated macrophages (P ≥ 0.05).
Macrophage cytokine production was measured in the supernatants 3 and 24 h 
after infection. After 3 h of infection, there was no production of IL-1β, IL-6, and 
IL-10 by macrophages. All tested cryptococcal species induced IL-8 and TNF-α 
production in macrophages after 24 h; C. gattii sensu stricto induced higher levels of 
IL-8 than those induced by C. bacillisporus (P ≥ 0.05) (see Fig. S1 in the supplemental 
material). Preactivated macrophages with IFN-γ produced higher levels of TNF-α 
after 24 h of infection with C. neoformans sensu stricto than those produced by 
nonpreactivated macrophages infected with C. neoformans sensu stricto (P ≥ 0.05); 
however, no differences were found among other species.
Cryptococcus bacillisporus and C. deuterogattii induced higher levels of 
ROS production than those induced by the other species 
All species within the C. gattii complex induced smaller amounts of reactive oxygen 
species (ROS) than those seen with Candida albicans. Cryptococcus decagattii, 
C. gattii sensu stricto, C. tetragattii, and an interspecies hybrid (C. neoformans sensu 
stricto × C. gattii sensu stricto) showed the lowest levels of ROS. On the other hand, 
human PBMCs produced high levels of ROS when stimulated with C. bacillisporus, 
C. deuterogattii, and C. flavescens, with peak of ROS production at 11 to 19 min (Fig. 4B).
The mRNA expression levels of inducible nitric oxide synthase (iNOS) and the 
antimicrobial peptides β-defensin 2 and cathelicidin were measured quantitatively 
(Fig. S2). Cryptococcus neoformans sensu stricto downregulated and the C. gattii 
species complex did not change iNOS expression (Fig. S2A). Similarly, no change in 
β-defensin 2 mRNA expression was detected (Fig. S2B). Overall, the interspecies hybrid, 
C. bacillisporus, C. decagattii, and C. gattii sensu stricto downregulated the expression 
of cathelicidin in human PMBCs in vitro (Fig. S2C). The main results found are 
























































































































































































































































































































































































































































































































































In this study, we demonstrate that species of the C. gattii complex present different 
abilities to induce cytokines in human cells. Cryptococcus bacillisporus and 
C. deuterogattii induced lower levels of production of the proinflammatory cytokines 
TNF-α, IL-1β, and IL-6 by human PBMCs than those induced by the other species. 
Cryptococcus gattii sensu stricto induced higher levels of the proinflammatory 
cytokines TNF-α, IL-1β, and IL-6 and higher levels of the anti-inflammatory 
cytokine IL-10 than those observed with other species of the C. gattii complex. The 
interspecies hybrid, C. decagattii, and C. gattii sensu stricto induced high levels of 
the proinflammatory cytokines TNF-α and IL-6. All cryptococcal species induced low 
levels of IFN-γ and IL-17 compared to those induced by another medically important 
yeast, Candida albicans, used as a positive control.
The decrease of proinflammatory cytokines may favor an environment that 
disturbs maturation and epitope presentation by dendritic cells, leading to 
suboptimal levels of the Th1 and Th17 responses, which are protective against 
cryptococcosis and provide fungal clearance [29, 30, 42, 43]. IL-1α and IL-1β 
are important in the host defense against fungal infections, activating innate 
immune cells and modulating adaptive immunity [44, 45]. In addition, high levels 
of the proinflammatory cytokines IL-6, IL-8, IFN-γ, and TNF-α in serum have been 
associated with cryptococcal meningitis survival in HIV patients [46]. Schoffelen and 
colleagues observed that heat-killed C. gattii species complex members induced 
higher concentrations of the proinflammatory cytokines IL-1β, IL-6, TNF-α and IL-
17/22 than those seen with the C. neoformans species complex [47]. However, 
they did not investigate differences among species of the C. gattii complex. Only 
C. deuterogattii induced significant production of IL-22, with clear differences 
among the species. IL-22 is a proinflammatory cytokine that promotes antimicrobial 
molecule production by epithelial cells and may have a protective role against 
infections [48], including cryptococcal infections. Meningitis caused by members 
of the C. gattii species complex in non-HIV-infected patients has been associated 
with low levels of the proinflammatory cytokines IFN-γ, TNF-α, and IL-6 and high 
levels of the anti-inflammatory cytokine IL-10 [49]. In the present study, C. gattii 
sensu stricto and the predominantly environmental species C. flavescens induced 
high levels of IL-10, while other species of the C. gattii complex induced low levels 
of IL-10. According to Angkasekwinai and coworkers, C. gattii sensu stricto and C. 
deuterogattii downregulate pulmonary chemokine expression, leading to a failure to 
mount protective immunity in immunocompetent hosts [29] and thus contributing 
to the disease process. It may be that differences in immune responses or clinical 
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aspects of immunocompetent hosts preferentially infected by C. gattii sensu stricto 
or C. deuterogattii are due to the differential levels of cytokines induced in PBMCs, as 
we showed that these species lead to production of different amounts of cytokines.
Our results showed that all cryptococcal species induced low levels of IFN-γ, and 
the use of IFN-γ in macrophages preactivation did not improve the phagocytosis 
rate or reduce the infection, even for C. neoformans sensu stricto. However, this 
cytokine increased TNF-α production in C. neoformans sensu stricto-infected 
human macrophages (see Fig. S1 in the supplemental material). Ikeda-Dantsuji and 
colleagues also showed that preactivation with IFN-γ did not promote phagocytosis 
of C. deuterogattii but that IFN-γ increased the phagocytic rate of C. neoformans 
sensu stricto [50]. Since IFN-γ has been associated with a good prognosis for 
cryptococcosis [46, 51, 52], these findings may be important for understanding 
the pathogenesis of cryptococcosis. In our experiments, IFN-γ did not significantly 
increase the TNF-α production of macrophages after infection with C. bacillisporus or 
C. gattii sensu stricto, which would affect the efficiency of macrophages at controlling 
cryptococcal growth. Wang and colleagues observed low levels of serum IFN-γ in 
immunocompetent patients with pulmonary cryptococcosis, and after antifungal 
treatment the serum levels of IFN-γ increased and the protective inflammatory 
response was restored. They suggested that cryptococcal infection may suppress 
the immune system and that its elimination helps to establish the immune system 
again [52]. In addition, the use of IFN-γ in combination with standard therapy has 
been related to successful fungal clearance, resolution of symptoms, and restoration 
of immunological parameters [51, 53]. Improvements in general condition were also 
observed among non-HIV/nontransplant patients after administration of IFN-γ as 
adjuvant therapy [54]. Meningitis caused by C. gattii sensu lato in non-HIV-infected 
patients has been associated with low levels of IFN-γ and other proinflammatory 
cytokines in parallel with high levels of the anti-inflammatory cytokine IL-10 [49]. 
Thus, according to in vivo results, IFN-γ is important for controlling cryptococcal 
disease. The results obtained in in vitro experiments in the present study may have 
been affected by the assay conditions, such as the IFN-γ concentration and the time 
of macrophage exposure to this cytokine. Despite that possibility, for PBMCs, no 
differences in IFN-γ induction could be detected among the species of the C. gattii 
species complex.
Cryptococcus bacillisporus induced the highest production of ROS, induced small 
amounts of cytokines, and downregulated cathelicidin compared to those observed 
with the other species. In contrast, C. gattii sensu stricto induced low levels of ROS and 
high levels of cytokines and downregulated cathelicidin expression. We speculate 
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that ROS are important for controlling C. bacillisporus infection during the first 
hours of infection, as fewer viable C. bacillisporus cells than C. gattii sensu stricto cells 
were recovered after 3 h of infection. However, after the initial killing by ROS, the 
nonskilled C. bacillisporus cells were able to proliferate inside macrophages, which 
might explain the increased number of intracellular cryptococci after 24 h of infection 
(Fig. 3E). It might be that the production of cytokines by the different Cryptococcus 
species does not correlate with the virulence of the particular species. However, the 
combination of cytokine production and ROS production may be important in the 
host-microbe interaction that finally results in control of the microorganism (in this 
case C. bacillisporus). Although C. gattii sensu stricto had more viable cells after 3 h of 
infection, we observed a decrease in viable intracellular cryptococci after 24 h. We 
speculate that nonlytic exocytosis may have happened, as cryptococcal cells were 
observed outside macrophages after 24 h of incubation [27]. For this species, the 
combination of ROS and proinflammatory cytokines may increase the capacity of 
macrophages to control infection. The environmental species C. flavescens induced 
high concentrations of ROS and cytokine production by human PBMCs, suggesting 
that the host immune response is effective at eliminating this nonhuman pathogen; 
this may explain the small number of cases of cryptococcosis caused by this 
species [55]. However, C. neoformans and C. deuterogattii induced small amounts of 
cytokines and large amounts of ROS in the first hour of infection, showing the ability 
to escape and survive inside macrophages, in accordance with previous studies [56, 
57-61]. Hole and coworkers observed that ROS produced by human plasmacytoid 
dendritic cells are required for C. neoformans sensu stricto growth inhibition but are 
not the only mechanism used to control C. neoformans sensu stricto [62]. The control 
of the interspecies hybrid, C. gattii sensu stricto, and C. decagattii may be mediated 
by cytokine pathways in an ROS-independent manner. These species induced high 
concentrations of proinflammatory cytokines (TNF-α, IL-6, and IL-1β) which are 
essential for protection against cryptococcosis [43, 44, 46]. According to our results, 
neither iNOS nor β-defensin 2 seems to be involved in C. gattii species complex 
infection control, but other antimicrobial molecules might be involved.
In conclusion, C. bacillisporus and C. deuterogattii induced low levels of production 
of the proinflammatory cytokines TNF-α, IL-1β, and IL-6, and C. deuterogattii 
induced more IL-22 than that induced by C. tetragattii. In contrast, C. gattii sensu 
stricto stimulated high levels of production of the proinflammatory cytokines 
TNF-α, IL-1β, and IL-6 and high levels of the anti-inflammatory cytokine IL-10. 
Despite ROS being important for controlling C. bacillisporus infection at the 
beginning of infection, nonkilled C. bacillisporus cells are able to proliferate inside 
macrophages, maintaining the infection. On the other hand, for C. gattii sensu 
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stricto, the combination of ROS and proinflammatory cytokine production may be 
involved in infection control. Overall, the species within the C. gattii complex have 
different abilities to induce cytokine production and ROS by human PBMCs. We 
have to be aware that host variability is an important factor in determining disease 
processes, and we cannot exclude the possibility that differences in exposure time 
or concentrations of fungi or the variation in the host defense systems of the human 
donors may have affected the outcomes of the comparison experiments. Our 
results with regard to differences in cytokine and ROS production in response to the 
members of the C. gattii species complex might contribute to the understanding of 
the cryptococcosis disease process.
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Fig 4. ROS production induced by cryptococcal species. Human PBMCs (1 × 106 cells/ml) from 
healthy volunteers were stimulated with zymosan (positive control; 1 mg/ml), live yeast forms of 
Cryptococcus species (5 × 106 cells/ml), or heat-killed Candida albicans (as a control; 1 × 107 cells/ml), 
and ROS production was measured by chemiluminescence assay. Data represent mean RLU (n = 6 [in 
quadruplicate]) for two independent experiments, with data collected every 2 min 23 s for 1 h. (A) 
Integral levels of PBMC ROS production induced by controls and Cryptococcus species. *, P ≥ 0.05; **, 
P ≥ 0.01; ns, not significant. (B) Kinetics of PBMC ROS production induced by Cryptococcus species. 
(C) Kinetics of PBMC ROS production induced by controls. ^, Candida albicans.
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Fig 5. Representative scheme of cytokine profile and antimicrobial molecule production in human 
PBMCs induced by cryptococcal species. C. bacillisporus and C. deuterogattii induced low levels of the 
proinflammatory cytokines TNF-α, IL-1β, and IL-6, and C. deuterogattii also induced IL-22. In contrast, 
C. gattii sensu stricto induced higher levels of TNF-α, IL-1β, IL-6, and IL-10 than those induced by 
the other species. ROS are important for controlling C. bacillisporus infection in the beginning, but 
nonkilled C. bacillisporus cells are able to proliferate inside macrophages. Cryptococcus gattii sensu 
stricto infection control may be mediated by the combination of ROS and proinflammatory cytokine 
production.
Table 1. Summary of observed data
Regulationa
Species, Host Cytokine IL-22 IL-10 ROS Cathelicidin
Proliferation in 
macrophages
C. gattii s.s, immunocompetent ↑ ↑ ↓ ↓ ↓
C. deuterogattii, immunocompetent ↓ ↑ ↑
C. bacillisporus, immunocompromised ↓ ↑ ↑
C. decagattii, immunocompromised ↑ ↓
C. tetragattii, immunocompromised ↑ ↓
C. neoformans, immunocompromised ↓
C. flavescens, environmental ↑ ↑




Eight cryptococcal strains were obtained from the Westerdijk Fungal Biodiversity 
Institute (Utrecht, the Netherlands). The details of these isolates are provided in 
Table 2. The yeast isolates were grown on Sabouraud dextrose agar plates, and a 
suspension of each isolate was prepared in sterile phosphate-buffered saline (PBS), 
pH 7.4 (1,000 × g, 10 min, 10°C). The cell viability was checked by dilution in 0.01% 
trypan blue in PBS, and cells were counted by use of a hemocytometer. Cryptococcus 
neoformans sensu stricto was used as a control instead of C. deneoformans because 
it is predominant worldwide and is related to the majority of cryptococcosis cases 
caused by C. neoformans species complex infection [39, 64].
Candida isolate 
Heat-killed Candida albicans ATCC MYA-3573 (UC 820) diluted in sterile PBS was 
used as a positive control for cytokine stimulation.
PBMC isolation and stimulation 
Buffy coats from healthy donors were obtained after written informed consent 
(Sanquin Blood Bank, Nijmegen, the Netherlands). Human peripheral blood 
mononuclear cell (PBMC) isolation was performed by dilution of blood in PBS and 
differential density centrifugation over Ficoll-Paque density gradient medium (GE 
Healthcare, Uppsala, Sweden). Cells were washed three times in sterile PBS and 
then suspended and cultured in RPMI 1640 medium (Gibco-Life Technologies, 
Carlsbad, CA, USA) supplemented with 10 mM pyruvate, 10 mM L-glutamine, 
100 U/ml penicillin, and 100 µg/ml streptomycin (Sigma-Aldrich, Saint Louis, MO, 
USA). Subsequently, cells were counted in a Coulter ZH counter (Beckman Coulter, 
Fullerton, CA, USA) and adjusted to 5 × 106 cells/ml. Thereafter, 100 µl aliquots of 
PBMCs (5 × 105 cells) were added to a round-bottomed 96-well plate and incubated 
with either 100 µl live Cryptococcus (2.5 × 106 cells/ml) isolate, 100 µl of ultrapure 
Escherichia coli lipopolysaccharide (LPS) (O111:B4; Sigma-Aldrich) (10 ng/ml), or 100 
µl of RPMI medium alone at 37°C and 5% CO2. All stimulations were performed in 
medium containing 10% human serum, which was obtained from a serum pool from 
healthy volunteers. After 24 h or 7 days, supernatants were collected and stored at – 
20 °C until they were used for assays. After 24 h, the cell monolayers were collected 
by adding 100 µl of 0.5% Triton X-100 to measure intracellular cytokine production 




Monocyte-derived TNF-α, IL-6, IL-1β, IL-8, and IL-10 levels in culture supernatants 
after 24 h of incubation were determined by use of commercial enzyme-linked 
immunosorbent assay (ELISA) kits (Sanquin, Amsterdam, the Netherlands [IL-
6, IL-8, and IL-10], and R&D Systems, Minneapolis, MN, USA [TNF-α and IL-1β]), 
and intracellular IL-1β protein in cell lysates collected by use of Triton X-100 was 
measured by another ELISA (R&D Systems) according to the manufacturer’s 
instructions. In preliminary experiments, we determined that 24 h was the time of 
maximum levels of monocyte-derived cytokine production for each species (data 
not shown). The levels of T-cell-derived cytokines IFN-γ, IL-17, and IL-22 in culture 
supernatants after 7 days of incubation were determined using ELISA kits (Sanquin 
[IFN-γ] and R&D Systems [IL-17 and IL-22]). Results are presented in picograms per 
milliliter.
Macrophage infection assay 
Primary monocytes were obtained by hyperosmotic Percoll (Sigma-Aldrich) density 
gradient centrifugation of PBMCs. Afterward, cells were washed once with PBS and 
seeded in tissue culture plates at 37°C and 5% CO2 in the presence of RPMI medium 
supplemented with 10% human pooled serum and GM-CSF (50 ng/ml) (R&D 
Systems). After 6 days of differentiation, macrophages were harvested by use of 
cold PBS and adjusted to 5 × 106 cells/ml. Thereafter, 200 µl aliquots of macrophage 
suspension (2 × 105 cells/ml) were added to 24-well plates, with or without glass 
coverslips. Macrophages were left to adhere for 30 min and preincubated with 
or without recombinant human IFN-γ (rhIFN-γ) (50 U/ml; Boehringer Ingelheim, 
Alkmaar, the Netherlands) for 1 h. Thereafter, cultures were infected with 1 × 
106 (multiplicity of infection [MOI] = 5:1) live yeast forms of C. neoformans sensu 
stricto, C. bacillisporus, or C. gattii sensu stricto. After 3 h, noninternalized fungi 
were washed off, the medium was replaced, and cultures were incubated for 24 h. 
For wells without coverslips, after the incubation time (3 h or 24 h), macrophages 
were lysed with water and mechanical lysis, diluted 100× in PBS, and seeded onto 
Sabouraud dextrose medium. Plates were incubated for 48 to 72 h at 37°C for CFU 
quantification. For wells with coverslips, cells were fixed, stained with Giemsa 
stain (Merck Millipore, Billerica, MA, USA), and analyzed by light microscopy 
(magnification, ×1,000) to determine the infection index. Three hundred cells were 
analyzed, and the percentage of infected cells and the mean number of intracellular 
cryptococci per infected cell were determined. The infection index was calculated 
as follows: infection index = percentage of infected macrophages × mean number 
of intracellular cryptococci per macrophage.
68
ROS measurement 
Human PBMCs (1 × 106 cells/ml) were suspended in Hanks’ balanced salt solution 
and exposed to different concentrations of live yeast forms of Cryptococcus 
species (5 × 106 cells/ml). Heat-killed C. albicans and zymosan (1 mg/ml) 
(InvivoGen, Toulouse, France) were used as positive controls. ROS formation was 
measured by a chemiluminescence assay using luminol (5-amino-2,3-dihydro-
1,4-phthalazinedione) (5 mM; Sigma-Aldrich). The luminometer measured 
chemiluminescence in the integration mode at 37°C for 1 h after luminol was added. 
Results are presented as numbers of relative light units (RLU) per second.
mRNA expression by qPCR 
RNA isolation was carried out as reported previously [65]. RNA was precipitated 
with isopropanol and washed with 75% ethanol, followed by reconstitution in 
RNase-free water. Subsequently, RNA was reverse transcribed into cDNA by use of 
an iScript kit (Bio-Rad, Hercules, CA, USA). Diluted cDNA was used for quantitative 
real-time PCR (qPCR) analysis, which was done by using a StepOne Plus sequence 
detection system (Applied Biosystems, Foster City, CA, USA) with SYBR green master 
mix (Applied Biosystems). Primer sequences (see Table S1 in the supplemental 
material) for inducible nitric oxide synthase (iNOS), β-defensin 2, and cathelicidin 
were obtained from the Harvard Primerbank database. Primers were purchased 
from Biolegio (Nijmegen, the Netherlands). The mRNA analysis was done by the 
2-ΔΔCT method, and the results were normalized against those for the glyceraldehyde-









































































































































































































































































































































































































































































































































































































































































































































































































































Data are given as mean values with standard errors of the means (SEM). The Mann-
Whitney U test for unpaired, nonparametric data was used to compare differences 
in cytokine production between two groups. Two-way analysis of variance (ANOVA) 
with Bonferroni’s multiple comparison test was used when more than two groups 
were compared. GraphPad Prism 5.0 software (GraphPad, San Diego, CA, USA) was 
used to tabulate and analyze the data.
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β-defensin 2 forward 5’-GGTGTTTTTGGTGGTATAGGCG-3’
β-defensin 2 reverse 5’-AGGGCAAAAGACTGGATGACA-3’
Fig S1. Macrophages cytokine production induced by Cryptococcus species. Human primary 
GM-CSF-derived macrophages (n=6) (2 × 105 cells/mL) were infected with live Cryptococcus species 
(1 × 106 cells/mL). After 3 and 24 h of incubation, TNF-α and IL-8 production was determined in 
supernatants by ELISA. Mean values with SEM from three independent experiments are presented. 
Two-way ANOVA Bonferroni posttests were used to calculate the differences among the treatments 
for each species. Statistical significance values considered were p ≤ 0.05 (*), p ≤ 0.01 (**) and p ≤ 
0.001 (***).
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Fig S2. iNOS and antimicrobial molecules mRNA expression induced by Cryptococcus species. 
Human PBMCs (n=6) (5 × 105 cells/mL) from healthy volunteers were stimulated with yeas live forms 
of Cryptococcus species (2.5 × 105 cells/mL) and heat-killed C. albicans (1 × 107 cells/mL). After 24 
h of incubation the mRNA was isolated and quantitative real-time PCR (qPCR) was performed to 
determine iNOS, β-defensin 2 and cathelicidin mRNA expression. Quantitative qPCR values are 
presented as fold change compared with non-stimulated cells (RPMI). Mean values with SEM from 
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Abstract
Cryptococcosis is acquired from the environment by the inhalation of 
Cryptococcus cells and may establish from an asymptomatic latent infection 
into pneumonia or meningoencephalitis. The genetic diversity of a Cryptococcus 
neoformans species complex has been investigated by several molecular tools, 
such as multi-locus sequence typing, amplified fragment length polymorphism 
(AFLP), restriction fragment length polymorphism and microsatellite analysis. 
This study aimed to investigate the genotype distributions and antifungal 
susceptibility profiles of C. neoformans sensu lato isolates from southern Brazil. 
We studied 219 C. neoformans sensu lato isolates with mating- and serotyping, 
AFLP fingerprinting, microsatellite typing and antifungal susceptibility 
testing. Among the isolates, 136 (69%) were from HIV-positive patients. Only 
C. neoformans mating-type a and serotype A were observed. AFLP fingerprinting 
analysis divided the isolates into AFLP1/VNI (n = 172; 78.5%), AFLP1A/VNII (n = 19; 
8.7%), AFLP1B/VNII (n = 4; 1.8%) and a new AFLP pattern AFLP1C (n = 23; 10.5%). 
All isolates were susceptible to tested antifungals and no correlation between 
antifungal susceptibility and genotypes was observed. Through microsatellite 
analysis, most isolates clustered in a major microsatellite complex and Simpson’s 
diversity index of this population was D = 0.9856. The majority of C. neoformans 
sensu stricto infections occurred in HIV-positive patients. C. neoformans AFLP1/
VNI was the most frequent genotype and all antifungal drugs had high in vitro 
activity against this species. Microsatellite analyses showed a high genetic 
diversity within the regional C. neoformans sensu stricto population, and correlation 
between environmental and clinical isolates, as well as a temporal and geographic 
relationship.
Keywords: Cryptococcosis; Cryptococcus neoformans; amplified fragment length 




The basidiomycetous yeast genus Cryptococcus is widely distributed in nature, found 
in soil, avian excreta, tree hollows and decaying wood [1, 2]. Within the genus, the 
C. neoformans/C. gattii species complexes are the most important in medical 
mycology as they are the main etiologic agents of cryptococcosis [3, 4]. 
Cryptococcus infection is acquired from the environment by inhalation of fungal 
cells and may establish as an asymptomatic latent infection in immunocompetent 
hosts or cause pneumonia and meningoencephalitis in immunosuppressed 
patients [4]. This infection is a common complication among solid organ transplant 
recipients showing high morbidity and mortality (27 %) during the first year of post-
transplantation [5]. Among HIV infected patients, 223,100 new cases of cryptococcal 
meningitis occur annually, resulting in an estimated 181,100 death [6], especially in 
developing countries, where access to antiretroviral therapy is still limited [7].
The taxonomy of the Cryptococcus genus was recently revised [3, 8, 9]. Both 
C. neoformans varieties were raised to species (C. neoformans sensu stricto and 
C. deneoformans) and the five C. gattii genotypes were grouped into five species 
(C. gattii sensu stricto, C. bacillisporus, C. deuterogattii, C. tetragattii and C. decagattii) 
[3]. This subject has been discussed among the scientific community, with some 
researchers endorsing the use of ‘species complex’ instead of using the ‘seven 
recognized species’ concept [10]; while others endorse that the different C. 
neoformans/C. gattii genotypes need to be considered different species [11].
The genetic diversity of C. neoformans sensu lato has been investigated with several 
molecular tools, such as multilocus sequence typing (MLST) [12–14], amplified 
length fragment polymorphism (AFLP) fingerprinting [15], restriction fragment 
length polymorphism (RFLP) [16] and microsatellite analysis [17, 18]. Based on 
these molecular approaches C. neoformans s.s. contains three genotypes AFLP1/
VNI, AFLP1A/VNII and AFLP1B/VNII, C. deneoformans is genotype AFLP2/VNIV and 
the hybrid between C. neoformans s.s. and C. deneoformans is AFLP3/VNIII [3, 15, 19]. 
Moreover, interspecies hybrids were found between C. deneoformans and C. gattii 
s.s. (AFLP2/VNIV×AFLP4/VGI=AFLP8), C. neoformans s.s. and C. gattii s.s. (AFLP1/
VNI×AFLP4/VGI=AFLP9) and C. neoformans s.s. and C. deuterogattii (AFLP1/VNI_
AFLP6/VGII=AFLP11) [19–21].
Cryptococcus neoformans s.s. genotype AFLP1/VNI is globally the predominant 
molecular type and causes the majority of cryptococcal infections [22, 23]. 
Cryptococcus deneoformans is geographically restricted to Europe and North 
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America, and the interspecies hybrid occurs in high rates in Mediterranean Europe, 
while in other regions it is rarely encountered [15, 19, 22]. In Latin America, 
C. neoformans AFLP1/VNI is the most frequently observed genotype, but the 
distribution of other genotypes is variable according to the geographic location. 
Colombia and Brazil have the highest genotypic diverse populations on the South 
American continent [22, 23]; in addition, some studies have also demonstrated 
differences in circulating genotypes in each region of Brazil [24–26]. These findings 
suggest that molecular studies are needed to clarify the genetic diversity and 
distribution among each microhabitat [27]. Beyond the differences in geographical 
distribution, studies have suggested that differences in antifungal susceptibilities 
correlate with species and genotypes [17, 28, 29].
Considering this information, it is necessary to emphasize the importance 
of investigating epidemiological relationships of clinical and environmental 
C. neoformans s.l. isolates as well as the relationship with antifungal susceptibility 
profiles. This will allow for a better understanding of the behaviour of this fungus as 
a saprophyte in the environment and as a pathogen in mammals. This study aimed 
to investigate the genotypic distribution and antifungal susceptibility profiles of 
C. neoformans s.l. species complex isolates from southern Brazil.
Methods
Isolates and clinical data
For this multicentre study, 219 C. neoformans s.l. isolates, previously identified with 
conventional mycological techniques, were available from mycology laboratories at 
the Federal University of Paraná, Curitiba, Paraná; Federal University of São Paulo, 
São Paulo; Federal University of Santa Maria, Santa Maria; Universidade Estadual 
do Oeste do Paraná (Paraná Western Paraná State University), Cascavel; and Federal 
University of Uberlândia, Uberlândia, Brazil. In total, 197 originated from clinical, 19 
from environmental, two from veterinary samples and one was from an unknown 
source. The isolates were collected and stored between 1987 and 2015. For clinical 
isolates, we accessed the patients’ medical records to collect clinical information.
Genomic DNA extraction
The isolates were subcultured for 2 days at 30 °C onto Sabouraud dextrose agar for 
genomic DNA extraction. A loop full of cells was suspended in 300 μl bacterial lysis 
buffer (Roche Diagnostics, Almere, The Netherlands), followed by mechanical lysis 
in a MagNA Lyser (Roche Diagnostics) and centrifugation for 2 min at 12.000×g, and 
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inactivation at 100 °C for 10 min. Then 200 μl of the solution was used for automatic 
DNA extraction by using the MagNA Pure 96 platform (Roche) with a final elution 
volume of 100 μl [30].
Mating-type, serotype and genotyping
The mating-type was determined by partial amplification of the RUM1 gene as 
described before [31]. Cryptococcus neoformans s.l. strains 125.91 (=CBS10512; 
aA; AFLP1/VNI), H99 (=CBS8710; αA; AFLP1/VNI), JEC20 (=CBS10511; aD; AFLP2/
VNIV) and JEC21 (=CBS10513; αD; AFLP2/VNIV) were included as controls [31]. 
AFLP fingerprinting analysis was performed as previously described [30]. Raw data 
was analysed using BioNumerics version 7.5 (Applied Maths, Sint-Martens-Latem, 
Belgium) with Pearson’s correlation coefficient and unweighted pair group method 
with arithmetic mean clustering algorithm, DNA fragments in the range of 20 bp 
and to 600 bp were included in the analysis.
Microsatellite typing
The genetic relationship of C. neoformans s.l. isolates was investigated by using a 
nine-marker microsatellite panel as described before [18]. The minimum spanning 
tree was calculated using BioNumerics version 7.5 (Applied Maths, Sint-Martens-
Latem, Belgium) [18]. 
Antifungal susceptibility testing
Altogether, 109 isolates were randomly selected for antifungal susceptibility testing, 
which was performed according to CLSI protocol M27-A3 [32]. The antifungal 
agents tested were amphotericin B (Bristol Myers Squibb, Munich, Germany), 
fluconazole (Pfizer, Sandwich, UK), itraconazole (Janssen Pharmaceutica, Beerse, 
Belgium), voriconazole (Pfizer), posaconazole (Merck, NJ, USA), isavuconazole 
(Basilea Pharmaceutica, Basel, Switzerland) and flucytosine (ICN Pharmaceuticals, 
Zoetermeer, the Netherlands). The concentration ranges were 0.016 to 16 mg L-1 
for amphotericin B, itraconazole, voriconazole, posaconazole and isavuconazole, 
and 0.062 to 64 mg L-1 for fluconazole and flucytosine. Cryptococcus isolates were 
cultured onto Sabouraud dextrose agar for 48 h at 30 °C and the inocula were 
adjusted to 1 × 103 – 5 × 103 CFU mL-1 in 0.9% NaCl to perform the test. Candida 
parapsilosis ATCC 22019 and Candida krusei ATCC 6258 were used as quality controls. 
MIC was defined as the lowest concentration that produced complete growth 
inhibition for amphotericin B and a prominent decrease of growth (50 %) for other 
antifungal agents, compared with the drug-free growth control. Interpretation of 
MIC values was based on epidemiological cutoff values [33–35].
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Data analysis
MIC50 and MIC90 were obtained by ordering the data for each antifungal in ascending 
order and selecting the median and 90th quantile, respectively. Geometric mean 
MICs were calculated using Microsoft Office Excel 2010 software. When the MIC 
was higher or less than the dilutions tested, 1 log2 dilution higher or 1 log2 dilution 
lower was considered to calculate the geometric mean. A two-tailed Mann–
Whitney–Wilcoxon non-parametric test was applied to compare the MIC values 
between different C. neoformans genotypes. The test was performed by StatistiXL 




Among the 219 C. neoformans sensu lato isolates, 218 were serotype A and mating-
type α by qPCR and one isolate remained undetermined. AFLP fingerprinting 
analysis divided the isolates into four clusters (Fig. 1). Most of the isolates clustered 
together with reference strains for C. neoformans sensu stricto AFLP1/VNI (n = 172; 
78.5%). Nineteen isolates (8.7 %) belong to the subgroup AFLP1A/VNB/VNII, and four 
(1.8%) isolates belong to the minor genotype AFLP1B/VNII. Twenty-three (10.5%) 
isolates composed a singular cluster AFLP1C, with a new AFLP sub-genotype. One 
(0.5%) isolate had an AFLP profile not assigned.
Microsatellite genotyping and genetic diversity
When all nine microsatellite CNA markers were combined, 129 different 
microsatellite genotypes were distinguished among 219 isolates, 93 being unique 
microsatellite genotypes. Using Simpson’s diversity index (D), the discriminatory 
power for the complete set of nine microsatellite markers was 0.9856.
The relationship between different microsatellite genotypes is illustrated in Fig. 
2. There is a major cluster composed of 117 isolates differing from each other 
by one out of nine microsatellite markers (Fig. 2a). The distribution of clinical, 
environmental and veterinary isolates is shown in Fig. 2 (a). Overall, 14 out of 19 
environmental isolates represent unique microsatellite genotypes but they are 
close to clinical isolates with only one locus difference from each other, and five 
of them are grouped in a minor cluster. The composition of two minor clusters is 
mostly of isolates coming from HIV-positive patients (Fig. 2b). The comparison with 
AFLP distribution shows that AFLP1A/VNI isolates and AFLP1C are related to each 
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other differing in 0–4 loci (Fig. 2c). Most of the AFLP1A/VNB/VNII sub A isolates 
combine together in a minor cluster and represent environmental isolates (Fig. 2c). 
Interestingly, all AFLP1A/VNB/VNII sub B isolates cluster in a minor microsatellite 
complex and eight out of nine are from HIV-positive patients (Fig. 2c). Temporal 
distribution shows the presence of the same genotype over prolonged periods, 
being frequently isolated throughout almost three decades of study (Fig. 2d). When 
geographic distributions were considered, the isolates from different cities in the 
current study were highly related to each other, with clusters containing isolates 
from different locations (Fig. 2e).
Table 1. MIC of C. neoformans sensu stricto isolates from southern Brazil
Species Antifungal
MIC value ranges (mg L-1)
Range MIC50 MIC90 GM
C. neoformans – all genotypes (n=109) Amphotericin B <0.016-0.125 0.125 0.125 0.098
Fluconazole 0.125-8 0.5 0.5 0.516
Itraconazole <0.016-0.25 0.031 0.063 0.027
Voriconazole <0.016-0.125 0.031 0.031 0.021
Posaconazole <0.016-0.125 0.031 0.063 0.027
Isavuconazole <0.016-0.063 <0.016 0.031 0.011
Flucytosine 0.25-8 2 4 2.42
C. neoformans – AFLP1/VNI (n=99) Amphotericin B <0.016-0.125 0.125 0.125 0.099
Fluconazole 0.125-8 0.5 0.5 0.521
Itraconazole <0.016-0.25 0.031 0.063 0.026
Voriconazole <0.016-0.125 0.016 0.063 0.022
Posaconazole <0.016-0.125 0.031 0.063 0.027
Isavuconazole <0.016-0.063 <0.016 0.031 0.011
Flucytosine 0.25-8 2 8 2.519
GM, geometric mean.
Antifungal susceptibility testing
All isolates showed susceptible MIC values for the antifungal agents tested (Table 
1). The new triazoles had high activity against the genotypes tested with MIC 
ranges of <0.016 – 0.125 mg L-1 for voriconazole and posaconazole and <0.016 – 
0.063 mg L-1 for isavuconazole. For fluconazole, two genotype AFLP1/VNI isolates 
showed a MIC at the limit of wild-type population of 8 mg l-1. We also observed that 
flucytosine was the less effective antifungal agent, showing the highest geometric 
mean MIC of 2.42 mg L-1 among the antifungals tested. No significant differences 
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were observed among the genotypes AFLP1/VNI, AFLP1A/VNII and AFLP1B/VNII and 
their respective antifungal susceptibility profiles (Mann–Whitney–Wilcoxon’s test, 
amphotericin B P = 0.319; fluconazole P = 0.386; itraconazole P = 0.548; voriconazole 
P = 0.121; posaconazole P = 0.092; isavuconazole P = 0.431; flucytosine P = 0.191).
Clinical data
Among the clinical isolates, 136 (69%) were isolated from HIV-infected patients 
and 29 (14.7%) were from patients with another immunosuppressive condition 
(transplant, n = 20; corticosteroid use, n = 4; other predisposing factors, n = 5). 
In addition, seven patients (3.6%) had no immunosuppressive condition and 25 
(12.7%) had an unknown immune status. The age ranged from 9 to 78 years, with a 
median of 38 years and the majority of patients were male (65%, n = 128).
Discussion
In the current study, 219 C. neoformans s.l. isolates from southern Brazil, collected 
during the period 1987–2015, were molecularly characterized and a randomly 
chosen subset was subjected to antifungal susceptibility testing. With qPCR 
sero- and mating-type determination, it was observed that all isolates, except 
one, were serotype A and mating-type α. Globally, the majority of the clinical and 
environmental C. neoformans s.s. isolates are mating-type α ([17, 22, 30, 36–39], 
present study). This feature suggests that C. neoformans s.s. is a predominantly 
clonal population with few recombination events and low genetic diversity that 
allows the maintenance of genomic markers associated with virulence [40, 41]. The 
presence of both mating-types facilitates sexual reproduction and recombination 
in a population. However, an exclusively mating-type a population may also have 
genetic recombination due to the capability of unisexual reproduction [42]. In 
specific geographic areas, for example India, unisexual reproduction is responsible 
for recombination and gene flow among C. neoformans s.s. populations [43]. In 
southern Africa mating-type a was found in 12% of C. neoformans s.s. clinical isolates 
obtained from HIV-positive patients [44], and among the clinical isolates from HIV-
positive patients from Zimbabwe, 7.3% of C. neoformans s.s. was mating-type a [45]. 
The presence of both mating-types among the African isolates is responsible for the 
genetic recombination within the C. neoformans s.s. population [45, 46].
Cryptococcus neoformans s.s. AFLP1/VNI is the most frequent genotype among 
clinical and environmental isolates around the world [22, 23]. In Brazil, this 
genotype has been isolated in 77.5–98% of the clinical and environmental isolates 
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[24, 26, 47]. This was also observed in the present study where 78.5% (n = 172) of C. 
neoformans isolates were genotype AFLP1/VNI. In other countries of Latin America, 
this genotype also has a high prevalence. In Argentina, all environmental isolates 
belong to genotype AFLP1/VNI [48, 49]. In Colombia, 97% of the clinical isolates are 
AFLP1/VNI [50] and 74.6% of C. neoformans clinical isolates in Mexico are AFLP1/VNI 
[51]. In Peru, genotype AFLP1/VNI was found in 50% of the isolates, but genotype 
AFLP1B/VNII was observed at a frequency of 34.4% [52], different from the present 
study and other Brazilian studies where genotype AFLP1B/VNII was rarely found 
[24, 38]. Interestingly, we found 23 isolates which clustered in a clade not described 
before, representing a new AFLP subgenotype (Fig. 1). The correlation between 
AFLP genotype and antifungal susceptibility has been discussed during the last few 
years, and variable data are available in the literature. Some studies have observed a 
correlation between the genotype and the antifungal susceptibility profile, showing 
that C. neoformans s.s. AFLP1/VNI was found to be less susceptible to amphotericin 
B, fluconazole, itraconazole and flucytosine when compared to C. deneoformans 
AFLP2/VNIV and the interspecies hybrid AFLP3/VNIV [17, 28, 29]. Similar to our 
results, in the Netherlands, Hagen and colleagues [17] observed less susceptible 
isolates for flucytosine and fluconazole with MIC ranges of 0.5 – 64 and 0.25 – 16 
mg L-1, respectively [17]. In contrast, some studies found no relation between C. 
neoformans AFLP genotypes and antifungal susceptibility [26, 27, 31, 52]. This is in 
agreement with the present study, where no correlation between subgenotype and 
antifungal susceptibility was found. Cryptococcosis caused by C. neoformans s.s. in 
Brazil is mainly found in median-aged male patients, diagnosed with HIV or another 
immunosuppressive condition ([25, 27, 38, 47, 53–55], present study). In agreement 
with other Latin American countries, in Brazil the majority of clinical C. neoformans 
s.s. isolates are from HIV-positive patients [48, 50, 56].
Microsatellites are tandem repeats present throughout the genome, but highly 
variable in number and repeat units for each individual within a population [57]. 
The higher mutation rates of microsatellite loci allow the investigation of intra-
population genetic diversity [58]. In studies when closely related isolates need to be 
differentiated, microsatellite typing may be highly informative [58]. This approach 
is a high-resolution tool to sub-type C. neoformans s.s., providing excellent 
discrimination between isolates from different sources and allowing epidemiology 
studies [17, 18, 59]. In our study, we observed a major microsatellite complex 
composed mainly of clinical isolates that differ from each other by one locus, with 
only a few environmental and veterinary isolates that were closely related (Fig. 2a). 
These results differ from Illnait-Zaragozí and colleagues [18], where clinical and 
environmental isolates were clustered separately, suggesting additional ecological 
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niches of C. neoformans s.l. in the environment and a different relation with hosts in 
Cuba [18]. However, the authors studied a large number of environmental isolates 
and our study had a dataset with the majority of isolates with a clinical background. 
We observed a relation between the microsatellite genotypes and AFLP genotypes 
(Fig. 2c), showing that each AFLP genotype clustered in different microsatellite 
clusters. Although both AFLP1A/VNB/VNII subgroups seem to be more genetically 
isolated, once both were in separated clusters. Temporal and geographic 
distribution showed that besides the presence of unique microsatellite genotypes, 
there are isolates from different locations and periods sharing similar microsatellite 
genotype and clustering together (Fig. 2d, e).
We observed high genetic diversity among the isolates of our dataset, Simpson’s 
diversity index was 0.9856, with 129 different microsatellite genotypes among 219 
isolates, 93 being unique. The genetic diversity of southern Brazilian isolates was 
lower than observed in Cuba (D = 0.993) where 104 genotypes were found among 
190 isolates and also lower than observed in the Netherlands (D = 0.994) where 196 
genotypes were found among 259 isolates [17, 18]. In an Asian study, 265 different 
genotypes were found among 493 isolates and the genetic diversity varied according 
to the country. Kuwait and Qatar showed the most diversity in the population (D 
= 1.000), followed by Japan (D = 0.998), Indonesia (D = 0.994), India (D = 0.983), 
China (D = 0.975) and Thailand (D = 0.968). The authors also observed a relation 
between antifungal-resistant profiles in three specific microsatellite complexes 
(MC2, MC3 and MC17) [59], which was not observed in the present study. In Brazil, 
Ferreira-Paim and colleagues [54], using the ISHAM consensus MLST scheme, found 
a highly clonal population structure of C. neoformans s.s. in southeastern Brazil, and 
less variability when compared to Africa [54]. In contrast, our data showed high 
genetic diversity among C. neoformans s.s. isolates. However, different molecular 
approaches were used to analyse the genetic variability in both studies. MLST 
shows the polymorphisms in nucleotide sequences and allows the construction 
of a database; however, MLST fails to detect variability when the population has 
insufficient genetic variation, as occurs among individuals from a recent speciation 
[60]. Chen and colleagues [46] using MLST analysed the population structure of C. 
neoformans s.s. from Botswana and found evidence of a clonal network by eBURST 
analysis; however, STRUCTURE and SplitsTree analyses showed recombination 
events between the genotypes VNI and VNB [46]. A similar discrepancy was 
also observed by Nyazika and colleagues using microsatellite typing of 
C. neoformans s.s. from Zimbabwe [45]. Contradictory results were obtained from 
the same dataset, where disequilibrium linkage tests were significant, but Simpson’s 
diversity index showed a high genetic diversity.
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In conclusion, genotype AFLP1/VNI was the most frequent among the isolates 
studied and all C. neoformans sensu stricto isolates had low MICs of antifungal drugs. 
Microsatellite analysis revealed high diversity among the C. neoformans sensu 
stricto studied population with clinical, environmental and veterinary isolates being 
related to each other. In addition, the isolates showed a temporal and geographic 
relationship.
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Summary and general discussion
Epidemiological studies are important to recognize environmental reservoirs of 
Cryptococcus species and are sentinels for the appearance of different genotypes 
in the environment. The knowledge of circulating species and genotypes in a 
particular region where molecular diagnosis is not available it is necessary to predict 
the probable etiological agent of cryptococcosis cases. In addition, determination 
of the antifungal susceptibility allows the detection of non wild-type isolates and 
may help to choose a better therapy for these specific cases.
Chapter 2 is a review about worldwide ecological niches of C. gattii s.l., focusing on 
the ecoepidemiology of the C. gattii species complex in developing countries. We 
observed that C. gattii s.l. are distributed in a plethora of ecological niches and each 
year new reservoirs are discovered around the World. However, many countries 
have no epidemiological data available about Cryptococcus spp., clinical frequency 
or environmental distribution. In Brazil, cryptococcal epidemiologic information 
is limited, there being many regions unaware about the local epidemiology [1]. 
The majority of published data are from the Brazilian Southeast region, with few 
information from South, Midwest, Northeast and North regions [2-9]. The most 
frequently isolated species of environmental and clinical samples in Brazil are C. 
deuterogattii and C. neoformans s.s. [10]. Cryptococcosis caused by C. gattii s.s. and C. 
bacillisporus also occur in the South, Southeast and Northeast of Brazil. 
In chapter 3 it was observed that the studied isolates of C. deuterogattii belonged to 
mating-types a and α. The presence of both mating-types in nearly equal quantities 
may be related to recombination events among individuals of a population, being 
responsible for the genetic diversity observed among C. deuterogattii isolates [11]. 
However, most of the isolates from this study belonged to mating-type α therefore, 
recombination analyses should be performed to verify if this population has 
predominantly clonal or recombinant expansion. AFLP analysis showed the presence 
of two distinct clades representing new AFLP genotypes that were separated due 
to the presence of dominant markers. To identify which genetic markers made-up 
these new AFLP genotypes and its biological aspects of C. deuterogattii, Sequence 
Characterized AFLP Regions Multi-Locus Typing (SCAR-MLST) may be performed to 
verify the genomic locations of dominant markers and their influence on virulence 
traits, such as melanin and capsule production. A clinical isolate of C. deuterogattii 
(UFU986) was genetically indistinguishable from the highly virulent AFLP6A/VGIIa 
genotype that was responsible for a cryptococcosis outbreak on Vancouver Island, 
Canada (see Figure 1 in Chapter 3). This isolate was obtained in 2008 from a cerebral 
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spinal fluid sample of an apparently immunocompetent male patient who suffered 
from systemic hypertension as the sole medical history. In vitro susceptibility tests 
have shown that UFU986 is wild type for the antifungal tested. Virulence assays can 
be performed to investigate whether the virulence of UFU986 is comparable to the 
outbreak lineage of Vancouver Island [12]. In addition, the isolates G14 and G18 were 
obtained from immunocompetent patients, from the same city, and both developed 
pulmonary and central nervous system infections that were cured but remained 
with sequelae (see Figure 2, chapter 3). The first one (G14, mating-type a) was 
from a male patient who worked as a lumberjack at the time when cryptococcosis 
started; the second (G18, mating-type α) was a female patient who worked as a 
repository in a supermarket and reported constant contact with wooden boxes. We 
speculate that both patients may had been infected by C. deuterogattii during work 
activities, since they had constant contact with wood products which is the main 
environmental niche of the C. gattii species complex.
Species belonging to the C. gattii species complex vary in capsule and cell 
size, thermotolerance, geographic distribution and some species affect 
immunocompetent patients while others affect immunocompromised 
patients [13-15]. Results in chapter 4 show that the species have also 
different abilities to induce cytokines and antimicrobial molecules in 
human peripheral blood mononuclear cells (PBMCs). We observed that 
C. bacillisporus and C. deuterogattii induced the lowest levels of tumor necrosis 
factor alpha (TNF-α), interleukin-1β (IL-1β), and IL-6 among the five species of 
the C. gattii complex. Cryptococcus deuterogattii induced higher levels of IL-22 
than C. tetragattii. In addition, C. bacillisporus and C. gattii s.s. showed the ability 
to proliferate inside human monocyte-derived macrophages after 24 h of in vitro 
infection. All C. gattii s.l. species were able to generate reactive oxygen species 
(ROS) in human PBMCs, although C. bacillisporus and C. deuterogattii were more 
efficient than the other species. Overall, C. bacillisporus and C. deuterogattii induced 
lower levels of the proinflammatory cytokines TNF-α, IL-1β, and IL-6 and higher ROS 
levels than those induced by other species. Interestingly, Li et al. [16] investigated 
the association between human genetic variability and cytokine production in 
response to several bacterial, fungal, and viral stimuli. These authors found a 
single nucleotide polymorphism (SNP-rs4496335) related to TNF-α levels and with 
moderate association with IL-1β and IL-6 levels in response to C. deuterogattii 
(called Cryptococcus in the original article), this SNP was also related to IL1RN gene 
expression.  To confirm these results, the authors showed that the preincubation 
of PBMCs with the IL-1 receptor antagonist (IL-1Ra) inhibits the induction of TNF-α 
by C. deuterogattii [16]. The ability to cause disease in immunocompetent and 
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immunocompromised humans may be dependent on both the pathogen and 
host genetic characteristics [17-19]. Three isolates of each species of the C. gattii 
complex were tested and the differences observed after stimulation of PBMCs were 
dependent on the species and cytokine evaluated (data not shown). For C. gattii 
s.s. there was a significant difference between the isolates only in IL-10 production 
and for C. bacillisporus a significant difference was observed in IL-1β production. 
Genetic variability of the host is an important factor in the determination of disease 
processes, so additional studies focused on the investigation of the genomic or 
epigenetic profile may help to clarify how host variability and pathogen variability 
contribute to the establishment of diseases. 
In chapter 5 we observed that all isolates of C. neoformans s.l. were mating-type 
α and serotype A, most of them (n = 172; 78.5%) clustered with the AFLP1/VNI 
reference strain and 23 isolates (10.5%) composed a new AFLP genotype named 
here as AFLP1C. Interestingly, The AFLP1A sub B genotype was grouped into a 
smaller microsatellite cluster (MC) and 8 of 9 isolates from this cluster were from 
HIV-positive patients. Pan and colleagues [20] observed that most isolates of a 
specific microsatellite genotype, called MC8, were associated with HIV-positive 
patients, and MC17 had the majority of non-wild isolates for flucytosine. A 
relation between microsatellite and antifungal susceptibility was not observed in 
the present study. Microsatellite analyses revealed 129 different genotypes in a 
dataset of 219 isolates, with 93 unique genotypes. Most isolates (n = 117) clustered 
in a major MC differing from each other by 1 out of 9 microsatellite markers (see 
Figure 2a, chapter 5). Simpson’s diversity index showed a high genetic diversity 
(D = 0.9856) among Southern Brazilian C. neoformans s.s. isolates. In addition, we 
observed that many C. neoformans s.s. genotypes were isolated from different 
geographic regions throughout the three decades of study, suggesting that these 
genotypes are permanently settled in the environment. Clinical and environmental 
C. neoformans s.s. isolates were genetically related, differing from each other in one 
microsatellite locus. The same relationship was observed for the C. neoformans s.s. 
populations from Japan and Thailand [20]. In contrast, an epidemiological study 
conducted in Cuba revealed that clinical and environmental isolates of C. neoformans 
s.s. were grouped into different MCs, showing different environmental niches for 
this genotype [21]. A limitation of the present study was the presence of only 19 
environmental isolates. Future experiments have to address an environmental 
sampling to include more isolates of C. neoformans s.s. in the microsatellite analysis.
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In vitro antifungal susceptibility tests showed that C. neoformans and C. gattii species 
complex vary in their susceptibility, with higher MIC values  for the C. gattii species 
complex compared to the C. neoformans species complex [22-25]. In addition, 
differences in antifungal susceptibility were found also inside the complexes, with 
C. deuterogattii (AFLP6/VGII) and C. neoformans s.s. (AFLP1/VNI) showing less 
susceptibility to azoles [26-28] when compared to other species inside these complexes. 
In vitro antifungal susceptibility tests performed in chapters 3 and 5 showed that 
C. deuterogattii and C. neoformans s.s. isolates were wild-type to all antifungals 
tested. However, C. neoformans s.s. isolates showed high MICs to fluconazole and 
flucytosine. In vitro susceptibility may not predict response to in vivo treatment, 
therefore therapy for cryptococcosis is generally chosen according to the patient’s 
clinical manifestation and immune status, rather than considering the species 
involved in the infection [29]. However, susceptibility testing is useful for detecting 
special cases of resistance and thus assisting in the adoption of the best antifungal 
therapy.
As future prospects, SCAR-MLST analysis with C. deuterogattii isolates can 
be performed to verify the genomic location of the dominant markers of 
the new AFLP patterns in order to investigate whether these markers affect 
biological aspects of the fungus, such as virulence. On the other hand, 
virulence assays may be performed to investigate whether the virulence of 
UFU986 is comparable to the Vancouver Island outbreak lineage. In addition, 
further studies should focus on the investigation of the presence of specific 
SNPs related to susceptibility to cryptococcosis in order to verify how genetic 
variability of host and pathogen contribute to the establishment of the disease 
by different Cryptococcus species. Furthermore, the environmental isolation of 
C. neoformans s.s. should be carried out with the aim of including a larger number 
of environmental isolates in microsatellite analyses and thus obtain more robust 
information on the genetic relationship between the clinical and environmental 
isolates of C. neoformans s.s. in the studied region.
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Samenvatting en Discussie
Epidemiologisch onderzoek is belangrijk om omgevingsbronnen van Cryptococcus-
soorten te herkennen en zijn markers voor het verschijnen van verschillende 
genotypen in de omgeving. De kennis van circulerende soorten en genotypen in 
een bepaalde geografische regio, waar geen moleculaire diagnose beschikbaar is, 
is noodzakelijk om de vermoedelijke verwekker van cryptokokkose te voorspellen. 
Bovendien maakt bepaling van de antischimmelgevoeligheid de detectie van niet-
wild type isolaten mogelijk en kan het helpen om een  betere therapie voor deze 
specifieke gevallen te kiezen. 
Hoofdstuk 2 is een samenvatting van de wereldwijde ecologische niches van 
C. gattii s.l., met de nadruk op de epidemiologie van het C. gattii soortcomplex in 
ontwikkelingslanden. We hebben waargenomen dat C. gattii s.l. aanwezig is in een 
overvloed aan ecologische niches en jaarlijks worden wereldwijd nieuwe reservoirs 
ontdekt. Veel landen hebben echter geen epidemiologische gegevens beschikbaar 
over aanwezige Cryptococcus soorten, klinische frequentie of verspreiding in de 
omgeving. In Brazilië is epidemiologische informatie over cryptokokken beperkt, en 
in veel regio’s is de lokale epidemiologie onbekend [1]. De meeste gepubliceerde 
gegevens zijn afkomstig uit de Braziliaanse regio Zuid-Oost, met weinig informatie 
uit de regio’s Zuid, Midden-Westen, Noord-Oosten en Noorden [2-9]. De meest 
voorkomende soorten, geïsoleerd uit klinische en omgevingsmonsters in Brazilië 
zijn C. deuterogattii en C. neoformans s.s. [10]. Cryptokokkose door C. gattii s.s. en C. 
bacillisporus is ook waargenomen in de Zuid-, Zuidoost- en Noordoostelijke-regio’s 
van Brazilië [10]. 
In hoofdstuk 3 beschrijven we het voorkomen van C. deuterogattii van de mating 
types a en alfa in Brazilië. De aanwezigheid van beide mating typen in vrijwel 
gelijke hoeveelheden kan verband houden met recombinaties tussen individuen 
in een populatie, die verantwoordelijk zijn voor de genetische diversiteit die wordt 
waargenomen bij C. deuterogattii-isolaten [11]. De meeste isolaten in deze studie 
waren echter van het mating type α. Daarom zouden recombinatieanalyses moeten 
worden gedaan om te controleren of deze populatie een overwegend klonale of 
recombinante expansie vertoont.  AFLP-analyse toonde de aanwezigheid aan van 
twee verschillende clades met nieuwe AFLP-genotypen die werden gescheiden 
door de aanwezigheid van dominante markers. Om te onderzoeken welke 
genetische markers deze nieuwe AFLP-genotypes bij C. deuterogattii hebben 
gevormd zouden sequentieel gekarakteriseerde AFLP-gebieden met multi-locus-
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typering (SCAR-MLST) kunnen worden uitgevoerd.  Zo kunnen de genoom locaties 
van dominante markers en hun invloed op virulentie eigenschappen worden 
geverifieerd, zoals de vorming van melanine en capsules. Een Braziliaans klinisch C. 
deuterogattii isolaat (UFU986) bleek genetisch niet te onderscheiden te zijn van het 
zeer virulente uitbraak genotype AFLP6A/VGIIa op Vancouver Island, Canada (zie 
Figuur 1 in hoofdstuk 3). Dit isolaat werd in 2008 geïsoleerd uit hersenvocht van een 
schijnbaar immuuncompetente mannelijke patiënt zonder onderliggend lijden met 
alleen hypertensie. In vitro gevoeligheidstesten hebben aangetoond dat UFU986 
een wilde type gevoeligheidspatroon liet zien. Virulentietesten zouden kunnen 
worden uitgevoerd om te onderzoeken of de virulentie van UFU986 vergelijkbaar is 
met de Vancouver Island uitbraak isolaten  [12]. Bovendien werden ook de isolaten 
G14 en G18 verkregen van immuuncompetente patiënten, met lastig te genezen 
long- en centraal zenuwstelsel infecties uit dezelfde stad. (zie figuur 2, hoofdstuk 
3). De eerste stam (G14, mating type a), was afkomstig van een mannelijke patiënt 
die als houthakker werkte; de tweede (G18, mating type α) was een vrouwelijke 
patiënt die werkte in een supermarkt, waar ze veel contact had met houten kisten. 
We speculeren dat beide patiënten tijdens hun werk werden geïnfecteerd met 
C. deuterogattii, omdat ze voortdurend in contact zijn met houten producten, de 
plaats waar het C. gattii soortcomplex vaak wordt aangetroffen. 
Soorten die behoren tot het C. gattii soortcomplex variëren in capsulevorm en 
celgrootte, thermotolerantie, geografische spreiding en sommige soorten kunnen 
immuuncompetente patiënten infecteren [13-15]. De resultaten gepresenteerd in 
hoofdstuk 4 laten ook zien dat sommige soorten verschillen in hun vermogen om 
cytokines en antimicrobiële moleculen te induceren door mononucleaire cellen 
verkregen uit perifeer bloed van vrijwilligers (PBMC’s). We hebben waargenomen dat 
C. bacillisporus en C. deuterogattii het minste de PBMCs aanzette tot productie van 
tumornecrosefactor-alfa (TNF-α), interleukine-1β (IL-1β) en IL-6 vergeleken met 
de vijf soorten van het C. gattii soortcomplex. C. deuterogattii induceerde hogere 
niveaus van IL-22 dan C. tetragattii. Bovendien toonden C. bacillisporus en C. gattii 
s. s. het vermogen om te prolifereren in humane, van monocyten-afkomstige 
macrofagen na 24 uurs infectie in vitro. Alle C. gattii s.l. soorten waren in staat om 
reactieve zuurstofradicalen (ROS) te genereren PBMC’s, hoewel C. bacillisporus en 
C. deuterogattii efficiënter waren dan de andere soorten. Over het algemeen 
induceerden C. bacillisporus en C. deuterogattii lagere niveaus van de pro-
inflammatoire cytokinen TNF-α, IL-1β en IL-6 en hogere ROS-spiegels dan andere 
soorten. Li en collega’s onderzochten het verband tussen humane genetische 
variabiliteit en cytokineproductie na blootstelling aan verschillende bacteriële, 
schimmel- en virale stimuli hebben [16]. Deze auteurs vonden een enkel nucleotide 
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polymorfisme (SNP-rs4496335) gerelateerd aan de hoogtes van TNF-α waardes en 
een matige verband met IL-1, 1β en IL-6 waardes na stimulatie met C. deuterogattii 
(genaamd Cryptococcus in het originele artikel). Deze SNP was ook gerelateerd aan 
de expressie van het IL1RN-gen. Om deze bevindingen te bevestigen, toonden de 
auteurs aan dat pre-incubatie van PBMC’s met de IL-1-receptorantagonist (IL-1Ra) de 
inductie van TNF-α door C. deuterogattii remt [16]. Het vermogen van verschillende 
Cryptococcus soorten om ziekten te veroorzaken bij immuuncompetente 
en immuungecompromiteerde mensen kan afhankelijk zijn van inherente 
eigenschappen van de pathogenen en gastheren [17-19]. We testten drie stammen 
van elke soort in het C. gattii soortcomplex en de verschillen na stimulering 
door PBMC’s bleken afhankelijk te zijn van de species en type cytokine dat werd 
geëvalueerd. Voor C. gattii s.s. was er alleen een significant verschil tussen stammen 
bij de IL-10-productie en voor C. bacillisporus was er een significant verschil in IL-
1β-productie. Genetische variabiliteit tussen patiënten is een belangrijke factor 
bij het bepalen van ziekteprocessen en verdere studies gericht op onderzoek naar 
genomische of epigenetische profielen kunnen helpen om duidelijk te maken 
hoeveel variabiliteit van de gastheer en hoeveel van pathogenen bijdraagt  tot het 
ontstaan  van cryptokokkose. 
In hoofdstuk 5 wordt beschreven dat alle onderzochte Braziliaanse isolaten mating 
type a en serotype A waren, waarvan de meeste (n = 172; 78,5%) geclusterd waren 
met de AFLP1/VNI-referentiestam en 23 isolaten (10,5%) een nieuw AFLP-genotype 
lieten zien, AFLP1C. Interessant was dat AFLP1A subgroep B zich bevond in een 
klein microsatellietcluster (MC) en dat 8 van de 9 isolaten afkomstig waren van 
HIV-positieve patiënten. Pan en collega’s [20] zagen eerder dat de meeste isolaten 
van MC8 geassocieerd bleken te zijn met HIV-positieve patiënten en MC17 de 
meeste niet-wildtype gevoelige isolaten had voor flucytosine. Een verband tussen 
microsatelliet genotype en antifungale gevoeligheid werd niet waargenomen in 
ons onderzoek. Microsatelliet analyses onthulden 129 verschillende genotypen in 
een dataset van 219 isolaten, met 93 unieke genotypen. De meeste isolaten (n = 
117), geclusterd in een groot MC complex verschilden van elkaar in slechts 1 van de 
9 microsatellietmarkers (zie Figuur 2a, hoofdstuk 5). De Simpson diversiteitsindex 
toonde een hoge genetische diversiteit (D = 0,9856) bij de Zuid-Braziliaanse C. 
neoformans s.s. isolaten. Bovendien stelden we vast dat veel C. neoformans s.s. 
genotypen afkomstig waren uit verschillende geografische regio’s gedurende 
de drie decennia van onderzoek, hetgeen suggereert dat deze genotypes 
permanent in het milieu aanwezig zijn. Klinische en omgevings C. neoformans 
s.s. isolaten waren genetisch gerelateerd, met maximaal slechts verschillend voor 
één microsatelliet locus. Dezelfde relatie werd waargenomen voor C. neoformans 
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s.s. populaties uit Japan en Thailand [20]. Deze resultaten verschilden met 
epidemiologisch onderzoek uit Cuba, waar klinische en omgevingsisolaten in 
verschillende MC’s bleken te zijn geclusterd, met verschillende milieu-niches voor 
de genotypen [21]. Een beperking van de huidige studie was de analyse van slechts 
19 omgevingsisolaten. Toekomstige microsatellietanalyse studies moeten meer C. 
neoformans s.s. omgevingsisolaten includeren. 
In vitro antifungale gevoeligheidstests hebben aangetoond dat de complexen van C. 
neoformans en C. gattii-soorten variëren in gevoeligheid, met hogere MIC-waarden 
voor het C. gattii species complex in vergelijking met het C. neoformans species 
complex [22-25]. Bovendien werden verschillen in antischimmelgevoeligheid 
ook binnen de complexen gevonden, waarbij C. deuterogattii (AFLP6/VGII) en C. 
neoformans s.s. (AFLP1/VNI) de laagste gevoeligheid voor azolen lieten zien [26-
28] in vergelijking met andere soorten in deze complexen. In vitro antifungale 
gevoeligheidstests beschreven in hoofdstuk 3 en 5 toonden aan dat C. deuterogattii 
en C. neoformans s.s. isolaten een wildtype patroon lieten zien voor alle geteste 
antischimmelmiddelen. C. neoformans s.s. isolaten haden hoge MIC’s voor fluconazol 
en flucytosine. In vitro gevoeligheid kan de respons op behandeling in vivo niet 
voorspellen, daarom wordt de therapie van cryptokokkose over het algemeen meer 
gekozen op basis van klinische manifestatie en immuunstatus van de patiënt, dan 
op basis van de soort die bij de infectie betrokken [29]. 
In de toekomst kan SCAR-MLST-analyse met C. deuterogattii isolaten worden 
uitgevoerd om de genomische locatie van dominante markers van de nieuwe AFLP-
patronen te verifiëren en te onderzoeken of deze de biologische aspecten van de 
schimmel beïnvloeden zoals virulentie. Daarnaast moeten verdere studies gericht 
zijn op onderzoek naar de aanwezigheid van specifieke SNP’s gerelateerd aan 
gevoeligheid voor cryptokokkose om na te gaan hoe de genetische variabiliteit van 
gastheer en pathogeen bijdragen aan het ontstaan  van ziekte door verschillende 
Cryptococcus soorten. Tot slot is het belangrijk om meer niet-klinische C. 
neoformans s.s. uit het milieu in de microsatellietanalyses op te nemen en zo meer 
robuuste informatie te verkrijgen over de genetische relatie tussen klinische en 
omgevingsisolaten van C. neoformans s.s. in Zuid Brazilie.
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Resumo e discussão geral
Estudos epidemiológicos são importantes para identificar os reservatórios 
ambientais das espécies de Cryptococcus e são úteis como sentinelas para o 
aparecimento de diferentes genótipos no ambiente. O conhecimento das espécies 
e genótipos circulantes em uma região onde o diagnóstico molecular não está 
disponível é necessário para prever o provável agente etiológico dos casos de 
criptococose. E ainda, a determinação da suscetibilidade aos antifúngicos permite 
a detecção de isolados do tipo não selvagem e auxilia na escolha da melhor terapia 
destes casos específicos.
O capítulo 2 é uma revisão sobre os nichos ecológicos de C. gattii s.l., focando 
na epidemiologia das espécies de C. gattii em países em desenvolvimento. 
Observou-se que C. gattii s.l. estão distribuídos em uma ampla variedade de 
nichos ecológicos e que a cada ano novos reservatórios são descobertos ao 
redor do mundo. Contudo, muitos países não possuem dados epidemiológicos 
disponíveis sobre a frequência clínica de Cryptococcus spp. ou a distribuição 
ambiental. No Brasil, as informações sobre a epidemiologia de Cryptococcus 
spp. é limitada, com muitas regiões desconhecendo a própria epidemiologia 
[1]. A maioria dos dados publicados são da região Sudeste do Brasil e há poucas 
informações disponíveis das regiões Sul, Centro-Oeste, Nordeste e Norte [2-9]. 
As espécies mais frequentemente isoladas de amostras ambientais e clínicas 
no Brasil são C. deuterogattii e C. neoformans s.s. [10]. Criptococose causada por 
C. gattii s.s. e C. bacillisporus também ocorrem nas regiões Sul, Sudeste e Nordeste 
do Brasil [10]. 
No capítulo 3 observou-se que os isolados estudados de C. deuterogattii 
pertenciam aos mating-types a e α. A presença de ambos os mating-types em 
proporções semelhantes está relacionada com eventos de recombinação entre os 
indivíduos de uma população de C. deuterogattii, o que pode explicar a diversidade 
genética observada entre os isolados de C. deuterogattii [11]. Contudo, a maioria 
dos isolados deste trabalho pertenciam ao mating-type α por isso, análises de 
recombinação devem ser realizadas para verificar se esta população tem expansão 
predominantemente clonal ou recombinante. Análises de AFLP mostraram a 
presença de dois clados distintos representando novos genótipos de AFLP que foram 
separados devido a presença de marcadores dominantes. Para identificar quais 
marcadores genéticos compõem esses novos genótipos de AFLP e seus aspectos 
biológicos em C. deuterogattii, análises de Sequence Characterized AFLP Regions 
Multi-Locus Typing (SCAR-MLST) podem ser realizadas para verificar as localizações 
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genômicas de marcadores dominantes e sua influência sobre características de 
virulência como a produção de melanina e a produção de cápsula. Um isolado 
clínico de C. deuterogattii (UFU986) foi geneticamente indistinguível do genótipo 
altamente virulento AFLP6A/VGIIa que foi responsável por um surto de criptococose 
na Ilha de Vancouver, Canadá (ver Figura 1 no Capítulo 3). Este isolado foi obtido 
em 2008 a partir de uma amostra de líquor de um paciente do gênero masculino 
aparentemente imunocompetente que sofria de hipertensão sistêmica como a 
única doença de base. Testes de suscetibilidade in vitro mostraram que o UFU986 
é do tipo selvagem para os antifúngicos testados. Ensaios de virulência podem ser 
realizados para investigar se a virulência do UFU986 é comparável à linhagem do 
surto da ilha de Vancouver [12]. Além disso, os isolados G14 e G18 foram obtidos de 
pacientes imunocompetentes, da mesma cidade, e ambos desenvolveram infecções 
pulmonares e do sistema nervoso central que foram curadas, mas permaneceram 
com sequelas (ver Figura 2, capítulo 3). O primeiro isolado (G14, mating-type a) era 
de um paciente do gênero masculino que trabalhava como lenhador no momento 
em que a criptococose iniciou; o segundo (G18, mating-type α) era de uma paciente 
do gênero feminino que trabalhava como repositora em um supermercado e 
relatou constante contato com caixas de madeira. Nós especulamos que ambos 
os pacientes podem ter sido infectados por C. deuterogattii durante as atividades 
laborais, já que eles tiveram constante contato com produtos de madeira que é o 
principal nicho ambiental do complexo de espécies C. gattii.
Espécies pertencentes ao complexo de espécies C. gattii variam quanto ao tamanho 
da cápsula e célula, termotolerância, distribuição geográfica e, ainda, algumas 
espécies afetam pacientes imunocompetentes enquanto outras afetam pacientes 
imunocomprometidos [13-15]. Os resultados do capítulo 4 mostram que as 
espécies do complexo também têm diferentes habilidades para induzir citocinas e 
moléculas antimicrobianas em células mononucleares do sangue periférico humano 
(PBMCs). Observou-se que C. bacillisporus e C. deuterogattii induziram os menores 
níveis de fator de necrose tumoral alfa (TNF-α), interleucina-1β (IL-1β) e IL-6 entre 
as cinco espécies do complexo C. gattii. Cryptococcus deuterogattii induziu níveis 
mais elevados de IL-22 do que C. tetragattii. Além disso, C. bacillisporus e C. gattii 
s.s. mostraram a capacidade de proliferar dentro de macrófagos humanos derivados 
de monócitos após 24 h de infecção in vitro. Todas as espécies C. gattii s.l. foram 
capazes de gerar espécies reativas de oxigênio (ERO) em PBMCs humanas, embora 
C. bacillisporus e C. deuterogattii tenham sido mais eficientes que as outras espécies. 
No geral, C. bacillisporus e C. deuterogattii induziram níveis mais baixos de citocinas 
pró-inflamatórias TNF-α, IL-1β e IL-6 e níveis mais altos de ERO do que aqueles 
induzidos pelas outras espécies. Curiosamente, Li e colaboradores [16] investigaram 
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a associação entre a variabilidade genética humana e a produção de citocinas em 
resposta a vários estímulos bacterianos, fúngicos e virais. Esses autores encontraram 
um polimorfismo de nucleotídeo único (SNP-rs4496335) relacionado aos níveis 
de TNF-α e com moderada associação aos níveis de IL-1β e IL-6 em resposta ao C. 
deuterogattii (denominado Cryptococcus no artigo original), este SNP também foi 
relacionado com a expressão do gene IL1RN. Para confirmar estes resultados, os 
autores mostraram que a pré-incubação de PBMCs com o antagonista do receptor 
de IL-1 (IL-1Ra) inibe a indução de TNF-α por C. deuterogattii [16]. A capacidade de 
causar doença em humanos imunocompetentes e imunocomprometidos pode ser 
dependente tanto das características genéticas do patógeno quanto do hospedeiro 
[17-19]. Testou-se três isolados de cada espécie do complexo C. gattii e as diferenças 
observadas após a estimulação de PBMCs foram dependentes da espécie e citocina 
avaliada (dados não mostrados). Para C. gattii s.s. houve diferença significativa 
entre os isolados apenas na produção de IL-10 e para C. bacillisporus observou-se 
diferença significativa na produção de IL-1β. A variabilidade genética do hospedeiro 
é um fator importante na determinação dos processos de doença, sendo assim, 
estudos adicionais focados na investigação do perfil genômico ou epigenético 
podem ajudar a esclarecer o quanto a variabilidade do hospedeiro e a variabilidade 
do patógeno contribui para o estabelecimento das doenças. 
No capítulo 5 observamos que todos os isolados de C. neoformans s.l. eram do 
sorotipo A e mating-type A, a maioria deles (n = 172; 78,5%) foram agrupados 
com a linhagem de referência AFLP1/VNI e 23 isolados (10,5%) compuseram um 
novo genótipo de AFLP denominado aqui como AFLP1C. O genótipo AFLP1A sub 
B foi agrupado em um cluster menor de microssatélites (MC) e 8 de 9 isolados 
deste cluster foram provenientes de pacientes HIV-positivos. Pan e colaboradores 
[20] observaram que a maioria dos isolados de um genótipo de microssatélites 
específico, denominado MC8, estava associada a pacientes HIV-positivos, e o MC17 
apresentava a maioria dos isolados não-selvagens para flucitosina. A relação entre 
microssatélites e susceptibilidade antifúngica não foi observada no presente estudo. 
A análise de microssatélites revelou 129 genótipos diferentes em um conjunto de 
dados de 219 isolados, com 93 genótipos únicos. A maioria dos isolados (n = 117) 
foram agrupados em um MC principal, onde os isolados diferiram entre si em 1 
de 9 marcadores de microssatélites analisados (ver Figura 2a, capítulo 5). O índice 
de diversidade de Simpson mostrou alta diversidade genética (D = 0,9856) entre 
os isolados de C. neoformans s.s.. Além disso, observamos que muitos genótipos 
de C. neoformans s.s. obtidos de diferentes regiões geográficas ao longo das três 
décadas de estudo, sugerindo que esses genótipos estão permanentemente 
estabelecidos no ambiente. Isolados clínicos e ambientais de C. neoformans s.s. estão 
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geneticamente relacionados, diferindo um do outro em um locus de microssatélite. 
A mesma relação foi observada para as populações de C. neoformans s.s. do Japão 
e da Tailândia [20]. Em contraste, um estudo epidemiológico realizado em Cuba 
revelou que isolados clínicos e ambientais de C. neoformans s.s. foram agrupados 
em diferentes MCs, mostrando diferentes nichos ambientais para este genótipo 
[21]. Uma limitação do presente estudo foi a presença de apenas 19 isolados 
ambientais. Experimentos futuros devem abordar um isolamento ambiental para 
que seja possível incluir mais isolados ambientais de C. neoformans s.s. na análise de 
microssatélites.
Os testes de suscetibilidade a antifúngicos in vitro mostrou que as espécies dos 
complexo C. neoformans e C. gattii variam em sua suscetibilidade, com valores 
de CIM mais elevados para o complexo de espécies C. gattii em comparação 
com o complexo de espécies C. neoformans [22-25]. Além disso, diferenças na 
susceptibilidade a antifúngicos foram encontradas também dentro dos complexos, 
com C. deuterogattii (AFLP6/VGII) e C. neoformans s.s. (AFLP1/VNI) apresentando 
menor suscetibilidade aos azólicos [26-28] quando comparados às outras espécies 
desses complexos. Os testes de susceptibilidade a antifúngicos in vitro realizados 
nos capítulos 3 e 5 mostraram que todos os isolados de C. deuterogattii e C. 
neoformans s.s. são do tipo selvagem para todos os antifúngicos testados. No 
entanto, os isolados de C. neoformans s.s. apresentaram altas CIMs para fluconazol 
e flucitosina. A suscetibilidade in vitro pode não prever a resposta ao tratamento in 
vivo, portanto a terapia para criptococose é geralmente escolhida de acordo com a 
manifestação clínica e o estado imunológico do paciente, ao invés de considerar a 
espécie envolvida na infecção [29]. Entretanto, os testes de suscetibilidade são úteis 
para detectar casos especiais de resistência e, assim, auxiliar na adoção da melhor 
terapia antifúngica. 
Como perspectivas futuras, a análise SCAR-MLST com os isolados de 
C. deuterogattii pode ser realizada para verificar a localização genômica dos 
marcadores dominantes dos novos padrões de AFLP, a fim de investigar se estes 
marcadores afetam aspectos biológicos do fungo, como a virulência. Por outro lado, 
ensaios de virulência podem ser realizados para investigar se UFU986 apresenta 
virulência comparável com a linhagem do surto da Ilha de Vancouver. Além 
disso, outros estudos devem se concentrar na investigação da presença de SNPs 
específicos relacionados com a suscetibilidade à criptococose, a fim de verificar 
como a variabilidade genética do hospedeiro e do patógeno contribuem para o 
estabelecimento da doença pelas diferentes espécies de Cryptococcus. Além disso, 
o isolamento ambiental de C. neoformans s.s. deve ser realizado com o objetivo de 
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incluir um número maior de isolados ambientais nas análises de microssatélites e, 
assim, obter informações mais robustas sobre a relação genética entre os isolados 
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